[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 83 of about 83
1. Ryan DP, Kulke MH, Fuchs CS, Grossbard ML, Grossman SR, Morgan JA, Earle CC, Shivdasani R, Kim H, Mayer RJ, Clark JW: A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer; 2002 Jan 1;94(1):97-103
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
  • BACKGROUND: Patients with metastatic pancreatic carcinoma have a poor survival.
  • Chemotherapy with gemcitabine is the standard first-line treatment.
  • In a Phase II trial at one academic cancer center, the clinical safety and activity of combining gemcitabine and docetaxel were assessed.
  • METHODS: Patients with previously untreated, advanced pancreatic carcinoma were eligible.
  • Three patients had received prior chemoradiation for postresection adjuvant therapy.
  • One hundred forty-six cycles of chemotherapy were administered, and 5 cycles (3%) in 4 patients (12%) were complicated by febrile neutropenia.
  • CONCLUSIONS: The combination of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma is well tolerated and is associated with moderate activity despite aggressive dose reduction.
  • Whether combination regimens are more effective than single agents in the treatment of patients with pancreatic carcinoma awaits evaluation in randomized studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Paclitaxel / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Taxoids

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11815964.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


2. Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer; 2002 Feb 15;94(4):902-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
  • BACKGROUND: A prospective, randomized Phase III trial was performed to determine whether, compared with gemcitabine (GEM) alone, the addition of cisplatin (CDDP) to GEM was able to improve the time to disease progression and the clinical benefit rate in patients with advanced pancreatic adenocarcinoma.
  • The objective response rate, overall survival rate, and toxicity patterns of patients in the two treatment arms were evaluated as secondary end points.
  • METHODS: Patients with measurable, locally advanced and/or metastatic pancreatic adenocarcinoma were randomized to receive GEM (Arm A) or a combination of GEM and CDDP (Arm B).
  • In Arm A, a dose of 1000 mg/m(2) GEM per week was administered for 7 consecutive weeks, and, after a 2-week rest, treatment was resumed on Days 1, 8, and 15 of a 28-day cycle for 2 cycles.
  • Patients were restaged after the first 7 weeks of therapy and then again after the other 2 cycles.
  • The median time to disease progression was 8 weeks in Arm A and 20 weeks in Arm B; this difference was statistically significant (P = 0.048).
  • Toxicity was mild in both treatment arms, with no significant differences between the two groups except for the statistically higher incidence of Grade 1-2 asthenia in Arm B (P = 0.046).
  • CONCLUSIONS: The addition of CDDP to GEM significantly improved the median time to disease progression and the overall response rate compared with GEM alone.
  • The authors conclude that the combination of CDDP and GEM currently may be considered as an optimal treatment for patients with locally advanced and/or metastatic adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / pharmacology. Deoxycytidine / analogs & derivatives. Deoxycytidine / pharmacology. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10323
  • (PMID = 11920457.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


3. Bruckner HW, Hrehorovich VR, Sawhney HS: Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer. Anticancer Res; 2005 Sep-Oct;25(5):3637-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer.
  • A 74-year-old male, with refractory stage IV pancreatic cancer, was successfully treated with bevacizumab 5 mg/kg and combination chemotherapy consisting of gemcitabine, fluorouracil leucovorin, irinotecan and cisplatin (GFLIP) every two weeks.
  • The patient had rapidly failed initial treatment with GFLIP given in an identical dose and schedule.
  • Large new liver lesions developed during active treatment.
  • This is the first demonstrated benefit of bevacizumab used in combination with previously failed chemotherapy for pancreatic cancer.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bevacizumab. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Male

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101193.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


Advertisement
4. Davila JA, Chiao EY, Hasche JC, Petersen NJ, McGlynn KA, Shaib YH: Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer. Pancreas; 2009 Jan;38(1):e18-25
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer.
  • OBJECTIVE: We conducted a population-based study to describe the utilization, determinants, and survival effects of adjuvant therapies after surgery among older patients with pancreatic cancer.
  • METHODS: Using Surveillance, Epidemiology, and End Results-Medicare data, we identified patients older than 65 years who received surgical resection for pancreatic cancer during 1992-2002.
  • We constructed multiple logistic regression models to examine patient, clinical, and hospital factors associated with receiving adjuvant therapy.
  • Cox proportional hazards models were used to examine the effect of therapy on survival.
  • RESULTS: Approximately 49% of patients received adjuvant therapy after surgery.
  • Patient factors associated with increased receipt of adjuvant therapy included more recent diagnosis, younger age, stage II disease, higher income, and geographic location.
  • Hospital factors associated with increased receipt of adjuvant therapy included cooperative group membership and larger size.
  • Adjuvant treatments associated with a significant reduction in 2-year mortality (relative to surgery alone) were chemoradiation or radiation alone but not chemotherapy alone.
  • CONCLUSIONS: Our findings suggest that adjuvant chemoradiation and, to a lesser degree, radiation only are associated with a reduction in the risk of mortality among older patients who undergo surgery for pancreatic cancer.
  • However, receipt of adjuvant therapy varied by period and geography as well as by certain patient and hospital factors.
  • [MeSH-major] Health Services Accessibility / statistics & numerical data. Pancreatectomy / utilization. Pancreatic Neoplasms / therapy. Patient Selection
  • [MeSH-minor] Age Factors. Aged. Chemotherapy, Adjuvant / utilization. Female. Hospitals / statistics & numerical data. Humans. Income / statistics & numerical data. Kaplan-Meier Estimate. Logistic Models. Male. Medicare. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant / utilization. Residence Characteristics / statistics & numerical data. Retrospective Studies. Risk Assessment. SEER Program. Sex Factors. Time Factors. Treatment Outcome. United States / epidemiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] Med Care. 2002 Aug;40(8 Suppl):IV-3-18 [12187163.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2069-76 [7697596.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Surgery. 1997 Sep;122(3):553-66 [9308613.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1372-81 [15812554.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4532-7 [16002844.001]
  • [Cites] Arch Surg. 2006 Feb;141(2):137-42 [16490889.001]
  • [Cites] Dig Surg. 2005;22(5):321-8 [16254431.001]
  • [Cites] J Gastrointest Surg. 2006 Jun;10(6):813-22 [16769537.001]
  • (PMID = 18797424.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010158-12
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS526322; NLM/ PMC3835699
  •  go-up   go-down


5. Bang S, Jeon TJ, Kim MH, Park JY, Park SW, Chung JB, Song SY: Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma. Pancreatology; 2006;6(6):635-41
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma.
  • BACKGROUND/AIMS: Combination therapy of gemcitabine and cisplatin has been reported as an effective regimen for advanced pancreatic cancer.
  • A phase II study was undertaken to determine the efficacy of a single dose of cisplatin in combination with weekly gemcitabine in patients with metastatic pancreatic carcinoma.
  • METHODS: Patients with measurable, metastatic pancreatic carcinoma, not locally advanced diseases, were included.
  • The median time to progression was 6.1 months (95% CI, 4.16-7.98 months).
  • CONCLUSIONS: The modified regimen of a single dose of cisplatin per cycle in combination with weekly gemcitabine appeared to have a more favorable therapeutic index and comparable toxicity profiles.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Administration Schedule. Female. Humans. Injections, Intravenous. Korea / epidemiology. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel and IAP.
  • (PMID = 17159377.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Dickinson KJ, Gomez D, Lowe A, Gokhale JA, Ausobsky JR, Guillou PJ, Rahman SH: Carcinoma of the body of pancreas in evolution: an aggressive disease affecting younger patients? JOP; 2007;8(3):312-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the body of pancreas in evolution: an aggressive disease affecting younger patients?
  • CONTEXT: Pancreatic body carcinoma has a poor prognosis with advanced disease at presentation.
  • PARTICIPANTS: Thirty-one patients with pancreatic body carcinoma (median age at diagnosis 72 years; range 43-87 years).
  • There was a significantly (P=0.024) greater prevalence of more advanced tumours post MDT (stage IV: 15/23, 65.2%) than pre MDT (stage IV: 2/8, 25.0%).
  • Neither tumour markers nor liver biochemistry differentiated tumour stage.
  • Best supportive care was offered to 16 patients (51.6%) while 12 patients (38.7%) were suitable for chemotherapy: 2 out of 8 pre MDT (25.0%) and 10 out of 23 (43.5%) post MDT (P=0.433).
  • For stage III tumours, post MDT patients tended to be younger (median 59 years vs. 74.5 years, P=0.042).
  • Survival was not significantly increased after MDT introduction but chemotherapy offered significant survival benefit on multivariate analysis (P=0.042; hazard ratio: 0.39, 95% CI: 0.16-0.97).
  • CONCLUSION: The trend is towards increased prevalence of pancreatic body cancer and more advanced disease at presentation.
  • Chemotherapy was associated with a survival benefit, although the introduction of the MDT has not significantly altered disease management.
  • [MeSH-major] Pancreatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495360.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-19-9 Antigen
  •  go-up   go-down


7. Saif MW, Kang SP, Ledbetter L, Steg A, Diasio R, Johnson M: Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? JOP; 2007;8(6):799-805
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
  • CONTEXT: Capecitabine has shown efficacy in treatment of metastatic pancreatic cancer.
  • CASE REPORT: We report two patients with metastatic pancreatic carcinoma who had long-term survivals on capecitabine after gemcitabine failure.
  • We also describe a novel method of measuring thymidine phosphorylase level from serum without an invasive tissue biopsy.
  • CONCLUSION: Capecitabine resulted in long term survivals in two patients with metastatic pancreatic cancer after gemcitabine failure.
  • The use of capecitabine as second-line treatment in metastatic pancreatic cancer should be further explored along with the role of thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in its activity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Biomarkers / metabolism. Capecitabine. Dihydrouracil Dehydrogenase (NADP) / metabolism. Female. Humans. Male. Middle Aged. Pharmacogenetics. Survival Analysis. Thymidine Phosphorylase / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993734.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.4.2.4 / Thymidine Phosphorylase; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Tawada K, Ishihara T, Kobayashi A, Yamaguchi T, Tsuyuguchi T, Matsuyama M, Yokosuka O: Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis. Clin Cancer Res; 2008 Nov 15;14(22):7438-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis.
  • PURPOSE: In pancreatic carcinoma, vascular endothelial growth factor (VEGF) expression at the primary site has been suggested to be a prognostic parameter.
  • We quantitatively analyzed VEGF expression in liver metastases from pancreatic carcinoma and examined the correlation among VEGF expression in liver metastases, clinicopathologic factors, and clinical outcome.
  • EXPERIMENTAL DESIGN: The subjects consisted of 23 patients with pancreatic adenocarcinoma who had liver metastases and were treated with S-1 and gemcitabine as the first-line treatment.
  • VEGF expression was quantitated by enzyme immunoassay in biopsy specimens of liver metastases and nontumorous liver tissue, and in plasma.
  • In 10 of the 23 patients, VEGF expression was also quantitated in biopsy specimens of the primary pancreatic tumor.
  • All samples were collected before treatment.
  • RESULTS: The VEGF level in nontumorous liver tissue was 36.6 +/- 10.0 pg/mg protein versus 376.8 +/- 106.1 pg/mg protein in liver metastases (P = 0.0016).
  • Pretreatment VEGF levels in plasma and in primary pancreatic carcinoma did not correlate with VEGF levels in the corresponding liver metastases.
  • CONCLUSIONS: Evaluation of VEGF levels in liver metastases might be useful in assessing the prognosis of patients with metastatic pancreatic carcinoma who are under systemic chemotherapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Liver Neoplasms / metabolism. Pancreatic Neoplasms / metabolism. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Drug Combinations. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Oxonic Acid / administration & dosage. Prognosis. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18974391.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Vascular Endothelial Growth Factor A; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


9. David AK, Vaughn DJ, Holroyde CP, Armstead B, Haller DG: A phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-alpha 2a) in metastatic pancreatic carcinoma: a Penn Cancer Clinical Trials Group (PCCTG) trial. Am J Clin Oncol; 2000 Feb;23(1):37-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-alpha 2a) in metastatic pancreatic carcinoma: a Penn Cancer Clinical Trials Group (PCCTG) trial.
  • A phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil (5-FU), leucovorin, and inteferon alpha-2a in metastatic pancreatic carcinoma.
  • Four patients withdrew before receiving treatment and one patient was nonevaluable for response because of treatment-related toxicity.
  • Treatment-related hospitalization was significant.
  • We conclude that this biochemically modulated 5-FU regimen is ineffective treatment for advanced pancreatic carcinoma, with significant toxicity even in highly selected patients with an ambulatory performance status.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10683073.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Ting JC, Fukshansky M, Burton AW: Treatment of refractory ischemic pain from chemotherapy-induced Raynaud's syndrome with spinal cord stimulation. Pain Pract; 2007 Jun;7(2):143-6
MedlinePlus Health Information. consumer health - Raynaud's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of refractory ischemic pain from chemotherapy-induced Raynaud's syndrome with spinal cord stimulation.
  • We report the successful treatment of refractory ischemic pain from cisplatin-induced Raynaud's syndrome with spinal cord stimulation after failed pharmacologic management and surgical sympathectomy.
  • CASE REPORT: A 48-year-old man developed ischemic pain of the hands while undergoing cisplatin and gemcitabine chemotherapy for metastatic pancreatic carcinoma.
  • After extensive pharmacologic management and surgical sympathectomy failed to provide adequate analgesia, the patient underwent a percutaneous spinal cord stimulation trial followed by permanent implantation and received significant pain relief prior to succumbing to his illness.
  • Spinal cord stimulation provided effective therapy for refractory ischemic pain, even after failed sympathectomy.
  • [MeSH-major] Pain, Intractable / therapy. Raynaud Disease / complications. Spinal Cord / radiation effects. Transcutaneous Electric Nerve Stimulation / methods
  • [MeSH-minor] Drug-Related Side Effects and Adverse Reactions. Humans. Ischemia / etiology. Male. Middle Aged. Pain Measurement / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17559484.001).
  • [ISSN] 1533-2500
  • [Journal-full-title] Pain practice : the official journal of World Institute of Pain
  • [ISO-abbreviation] Pain Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Van Rijswijk RE, Jeziorski K, Wagener DJ, Van Laethem JL, Reuse S, Baron B, Wils J, EORTC GastroIntestinal Tract Cancer Cooperative Group: Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group. Eur J Cancer; 2004 Sep;40(14):2077-81
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group.
  • The aim of the study was to assess the response rate and toxicity of high-dose 24 h infusion of 5-fluorouracil (5FU) in metastatic adenocarcinoma of the pancreas.
  • Patients with measurable disease, performance status 0-2, and no prior chemotherapy were registered to receive cycles of leucovorin (LV) 500 mg/m2 (or l-LV 250 mg/m2 over 1 h followed by 5FU 2.6 g/m2 over 24 h, weekly for 6 weeks, followed by a 2-week rest.
  • Main grade 3/4 National Cancer Institute (NCI) common toxicity criteria toxicities (patients) were diarrhoea (n = 3), vomiting (n = 2) and hand-foot syndrome (n = 5).
  • Median time to progression was 7 weeks (95% CI: [6.4-11.7] weeks) and median survival 19 weeks (95% CI: [12-35] weeks).
  • In conclusion, high-dose 5FU and folinic acid is well tolerated, but has only modest activity in pancreatic cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Fluorouracil / administration & dosage. Leucovorin / administration & dosage. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Analgesics / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15341982.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antimetabolites, Antineoplastic; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Kurosaki I, Hatakeyama K: Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience. Chemotherapy; 2005 Oct;51(6):305-10
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
  • BACKGROUND: The effects of gemcitabine on postoperative adjuvant chemotherapy were evaluated in patients with stage IV pancreatic cancer.
  • PATIENTS AND METHODS: Nineteen patients with stage IV pancreatic cancer who had pancreatic resection with curative intent during the 5 years up to February 2003 were enrolled in this study.
  • Nine cases received postoperative adjuvant chemotherapy with biweekly administration of 1,000 mg/m(2) gemcitabine, while the remaining 10 cases underwent surgery without any adjuvant chemotherapy.
  • RESULTS: The chemotherapy was well tolerated with only mild symptomatic and hematologic toxicities.
  • The disease-specific cumulative survival rates of the chemotherapy and surgery-alone groups were 86 and 70% at 1 year, and 50 and 12% at 2 years, with a median survival of 20 and 14 months, respectively (p = 0.0255).
  • The disease-free interval was improved, and the occurrence of hepatic metastasis was reduced in the chemotherapy group compared with the surgery-alone group.
  • CONCLUSIONS: Adjuvant systemic chemotherapy utilizing gemcitabine was feasible with acceptable adverse effects, and showed some survival benefit in stage IV pancreatic cancer patients.
  • Further investigation into gemcitabine-based combination therapies is warranted.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Japan / epidemiology. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 16224180.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


13. Yamamitsu S, Kimura H, Yamada Y, Inui N, Hiyama S, Hirata K, Kimura Y, Koito K, Shirasaka T: [The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer]. Gan To Kagaku Ryoho; 2007 Jul;34(7):1059-66
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer].
  • The remedy, especially chemotherapy, for advanced pancreatic cancer is hardly ever successful in terms of efficacy rate and survival period, because it is virtually unable to contribute to the improvement of median survival time (MST).
  • Thus,we devised a new intermittent dosage regimen utilizing the cell cycle difference of normal GI tract, bone marrow cell and pancreatic cancer cell, making use of 5-FU (-->S-1), CDDP and paclitaxel in March 2002.
  • Ten patients with advanced pancreatic cancer (4 in Stage IVa and 6 in Stage IVb) were treated with this new regimen.
  • Although adverse effects related to this regimen were clinically manageable, it was difficult to improve MST of patients with advanced pancreatic cancer with chemotherapy alone including this regimen.
  • Hence, we devised another regimen with the joint use of radiotherapy along with the same chemotherapy regimen in January 2003.
  • Twenty patients with advanced pancreatic cancer (Stage IV) were treated with this regimen.
  • It is presently under way, and an efficacy ratio of 35.0%, 1-year survival ratio of 86.3% and 2-year survival ratio of 64.0% were obtained by May 2005, showing that this may contribute to the extension of survival time of Stage IV pancreatic cancer patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Anorexia / chemically induced. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Nausea / chemically induced. Paclitaxel / administration & dosage. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637542.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Höhler T, Staib L, Oettle H: [Treatment of advanced pancreatic carcinoma]. Onkologie; 2008;31 Suppl 5:29-31
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of advanced pancreatic carcinoma].
  • [Transliterated title] Therapie des fortgeschrittenen Pankreaskarzinoms.
  • Gemcitabine monotherapy extends survival times in locally advanced or metastatic pancreatic carcinoma compared with supportive treatment alone.
  • Among patients who develop skin lesions of grade 2 or more, giving erlotinib in addition doubles survival times - from 5.9 to 10.5 months.
  • Attempting therapy with gemcitabine plus erlotinib is therefore sensible.
  • In patients with a good performance status, survival times can be extended using the combinations gemcitabine plus capecitabine or gemcitabine plus platinum.
  • For second-line treatment, oxaliplatin, 5-FU, and folic acid can be used.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Deoxycytidine / analogs & derivatives. Palliative Care / methods. Pancreatic Neoplasms / drug therapy. Platinum / administration & dosage. Quinazolines / administration & dosage. Terminal Care / methods

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033702.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; 49DFR088MY / Platinum; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride
  • [Number-of-references] 8
  •  go-up   go-down


15. Viúdez A, Rodríguez J, De La Cámara J, Salgado E, Chopitea A, Gil-Bazo I, García-Foncillas J, Valero J, Espinós J, Martin-Algarra S: Triplet therapy with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. J Clin Oncol; 2004 Jul 15;22(14_suppl):4252

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triplet therapy with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
  • : 4252 Background: To determine the activity and tolerance of gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
  • METHODS: Thirty-two patients with confirmed diagnosis of stage IV pancreatic carcinoma, with a median age of 60 years and ECOG performance of 0 to 2 (59.4% ECOG 1), received gemcitabine 800 mg/m<sup>2</sup> intravenously (iv) days 1 and 14, cisplatin iv 75 mg/m<sup>2</sup> day 1, leucovorin 500 mg/<sup>2</sup> iv days 1 and 14 and 5-fluorouracil (FU) 2600 mg/m<sup>2</sup> iv days 1 and 14.
  • 87 % of patients were chemotherapy naive.
  • 13 % of patients had received prior chemotherapy, including cisplatin (6.3%), gemcitabine (6.3%), FU (6.3%) or docetaxel (3.1%).
  • RESULTS: The total number of courses administered was 148, with a median of 4 cycles per patient (range 1 to 14).
  • Grade III/IV leucopenia, neutropenia or anemia was found in 21.8 %, 37.5 % and 19.25 %, respectively.
  • Main non-haematological grade III/IV toxicities included asthenia (18.8 %) anorexia (12.5 %) and nausea (9.4 %).
  • 10 patients (31.3 %) progressed while on-therapy.
  • With a median follow-up of 25 months (range 5.6 to 52.83), the median time to progression was 4.67 months (95% CI: 3.61 to 5.73), and the median overall survival was 10.23 months (95% CI: 4.30 to 14).
  • CONCLUSIONS: The combination of gemcitabine, FU, leucovorin and cisplatin, has moderate activity in metastatic carcinoma of the pancreas at an expense of an acceptable toxicity profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Castellano DE, Gomez-Martin C, Cubedo Cervera R, Garcia Lopez J, Gomez-Sanz R, Gravalos C, Nuñez Sobrino J, Cortes-Funes H: Exploratory study of the subcutaneous fat gene expression profile in patients with metastatic pancreatic carcinoma treated with standard gemcitabine chemotherapy regimen. J Clin Oncol; 2009 May 20;27(15_suppl):e22220

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploratory study of the subcutaneous fat gene expression profile in patients with metastatic pancreatic carcinoma treated with standard gemcitabine chemotherapy regimen.
  • There are few examples where the endpoint is to assess the biology of the host response to the treatment of the tumor.
  • A large number of patients with pancreatic cancer present features of the cachexia syndrome and specially a marked weight loss.
  • It has been postulated that a "cytokine storm" is the cause of the profound effect that this cancer has on distant tissues.
  • This trial analyzed changes in the subcutaneous fat gene expression profile in relation with the clinical benefit variable with standard gemcitabine (G) treatment.
  • METHODS: Patients with histology confirmed advanced pancreatic cancer, adequate organ function and written informed consent.
  • Nine pts had pre and post treatment biopsies and 7 only pretreatment.
  • CONCLUSIONS: It is feasible to study prospectively the impact of cancer treatment on different tissue biomarkers and correlated with standard antitumor evaluation system.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964084.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Fahlke J, Ridwelski K, Schmidt C, Stübs P, Weber M, Eichelmann K, Kettner E, Hribaschek A, Lippert H: Combination chemotherapy with docetaxel and gemcitabine in patients with metastatic or locally advanced pancreatic carcinoma: results of a multicenter phase II study. J Clin Oncol; 2004 Jul 15;22(14_suppl):4101

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with docetaxel and gemcitabine in patients with metastatic or locally advanced pancreatic carcinoma: results of a multicenter phase II study.
  • : 4101 Background: Single-agent gemcitabine for palliative chemotherapy in pancreatic carcinoma results in low tumor response rates and minor prolonged survival.
  • This multicenter study investigated the efficacy of a combination of gemcitabine (G) and docetaxel (D) for locally advanced or metastatic pancreatic cancer (LAMPC) in terms of response rate and survival.
  • METHODS: Of 55 enrolled patients (pts) with LAMPC: 24 were female, the median age was 61 years (range: 39-72), 33 had primary metastatic disease, 17 had primary locally advanced inoperable disease, and 5 had relapsed or developed metastases post surgery.
  • Pts received optimal doses of both drugs from a previous dose-finding study: weekly G 1000 mg/m<sup>2</sup>and D 35 mg/m<sup>2</sup>on Days 1, 8, and 15, followed by 7 days rest.
  • Tumor response was assessed by ultrasonography (and computed tomography, if necessary), chest X-ray, tumor markers, and clinical examination.
  • RESULTS: A total of 195 therapy cycles were administered to 55 pts (median, 3; range: 1-11) and an overall response of 20% was achieved: 1 pt (1.8%) had a complete response, 10 (18.2%) had partial responses, 28 (50.9%) had stable disease, and 14 (25.5%) had disease progression.
  • One pt was untreated, while another refused therapy and was excluded from the study.
  • With 4 pts alive, median survival is 8.1 months and 1-year survival, 29% (16 of 55 pts).
  • CONCLUSIONS: Docetaxel plus gemcitabine is well tolerated and markedly increases response rate in pts with metastatic pancreatic carcinoma.
  • Current evidence supports testing this chemotherapy protocol in a phase-III setting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014507.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Chiappori A, Simon GR, Kvols L, Tetteh L, Mahany JJ, Lush R, Sullivan DM: Phase I trial of carboplatin, irinotecan and etoposide in advanced solid tumors. J Clin Oncol; 2004 Jul 15;22(14_suppl):2132

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carboplatin(C), Irinotecan(T) and Etoposide (E) are drugs with a broad spectrum of activity.
  • RESULTS: A total of 10 patients were enrolled from April 2002 to October 2002.Patient characteristics were M/F 5/5; age range 24 to 65, ECOG PS 0/1=1/9; number of prior treatments 0/1/2/3= 4/2/3/1; median number of cycles given=3 (range 1 - 8).
  • Tumor types enrolled were NSCLC = 3, Carcinoid = 3, and 1 each of Head and Neck Cancer, Mesothelioma, Sarcoma and Islet Cell Cancer of the pancreas.
  • In the first cohort of 4 patients, 2 second-cycle grade IV non-febrile neutropenia was observed.
  • Two deaths occurred in previously treated advanced stage NSCLC patients.
  • The subsequent cohort of 6 patients tolerated chemotherapy well with no first-cycle or second-cycle grade III or IV neutropenia or thrombocytopenia.
  • Further dose escalation was not attempted owing to 2/2 patients experiencing Grade IV neutropenia in the first cohort.
  • A phase II trial of extensive stage SCLC is planned with this regimen with correlative intra-tumoral top I and II estimations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016906.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Chatterjee A, Bhattacharya S, Chatterjee AK, Biswas J, Mukhopadhyay B: A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers.
  • : 3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, 'psorinum therapy,' in treating liver, gall bladder, pancreatic, and stomach cancers.
  • The secondary outcome measure of the study was to assess the side effects of the investigational anti-cancer drug (psorinum) if any.
  • METHODS: The drug psorinum (an alcoholic extract of scabies, scrub, slough, and pus cells) was administered orally at 0.01ml-0.02 ml/Kg body weight as a single dose in empty stomach per day and ongoing to all the participants along with allopathic and homeopathic supportive cares.
  • RESULTS: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study.
  • According to the AJCC/UICC TNM staging system, 7 (4.43%) of them diagnosed at stage II, 39 (24.68%) of them diagnosed at late stage II or early stage III and 112 (70.87%) of them diagnosed at late stage III or stage IV.
  • These participants did not receive any other conventional or investigational cancer treatments.
  • The participants report no side effects from the drug psorinum.
  • CONCLUSIONS: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers.
  • Double-blinded randomized controlled clinical trial should be done for further investigation of this alternative cancer treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Ueno M, Ohkawa S, Sakamoto Y, Miyakawa K, Miyagi Y: The analysis of EGFR expression and EGFR mutations in advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The analysis of EGFR expression and EGFR mutations in advanced pancreatic cancer.
  • : e15629 Background: The standard chemotherapy of advanced pancreatic cancer is still gemcitabine and recently gemcitabine + EGFR tyrosine kinase inhibitor (TKI)is noted to be positive on Phase III study.
  • In lung cancer, EGFR mutations (the deletion of exon 19, the point mutation of exon 18, 21) have been reported to be correlated with the effect of EGFR TKI.
  • On the other hand, such EGFR mutations were not reported to be recognized by the direct sequencing method in pancreatic cancer.
  • This time we examined EGFR expressions and EGFR mutations in advanced pancreatic cancer.
  • METHODS: We examined EGFR expressions immunohistochemically and EGFR mutations by Loop-Hybrid Mobility Shift Assay (LH-MSA) which is more sensitive than the direct sequencing method in the tissue obtained from percutaneous biopsies in advanced pancreatic cancer patients.
  • RESULTS: The subjects were 31 inoperable pancreatic cancer patients.
  • Patients received chemotherapy (gemcitabine: 10, S-1: 8, gemcitabine+S-1: 12, no treatment: 1).The UICC stages were as follows:stage II; 2, stage III; 6, stage IV; 23.
  • The tissues were obtaind from liver; 12, pancreas; 19.
  • Although LH-MSA were performed successfully in all patients, the same EGFR mutations as lung cancer were not detected.
  • CONCLUSIONS: EGFR expressions were not correlated with survivals and the same EGFR mutations as lung cancer were not detected in inoperable advanced pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Nakamura K, Yamaguchi T, Ishihara T, Ishiguro H, Kabayashi A, Tadenuma H, Saisyo H: A phase I/II study of gemcitabine (GEM) with oral S-1 in metastatic pancreatic carcinoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):4134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of gemcitabine (GEM) with oral S-1 in metastatic pancreatic carcinoma.
  • : 4134 Background: Gemcitabine (GEM) alone is the standard care for advanced pancreatic cancer.
  • We conducted a phase 1/2 study of GEM with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydropridine and potassium oxonate.
  • METHODS: Eligibility criteria was as follows: patients with metastatic pancreatic cancer, PS 0∼2, and normal renal, liver, and bone marrow functions.
  • Doses of each drug in the phase 1 part of this study were planed as follows: Level 1: S-1 60mg/m<sup>2</sup>/day GEM 800mg/m<sup>2</sup> Level 2a: S-1 80mg/m<sup>2</sup>/day GEM 800mg/m<sup>2</sup> Level 2b: S-1 60mg/m<sup>2</sup>/day GEM 1000mg/m<sup>2</sup> Level 3: S-1 80mg/m<sup>2</sup>/day GEM 1000mg/m<sup>2</sup> Phase 2 part is being conducted with doses based on the phase 1 results.
  • Three of 6 patients in level 2a showed DLT: one patient developed sepsis with grade 4 neutropenia, another patient developed grade 3 rash and the third patient developed grade 2 leucopenia not recovering within the specified period.
  • CONCLUSIONS: The combination chemotherapy of GEM and S-1 was well tolerated.
  • Although most of the patients had advanced disease, we observed a promising response rate (47%) with this combination chemotherapy.
  • Given these results it would be worthwhile to compare this therapy with GEM alone in the phase 3 studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014558.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Frontini L, Falconi M, Gallo C, Di Maio M: A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol; 2009 May 20;27(15_suppl):4504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.
  • : 4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC).
  • The GIP-1 randomized phase III trial (clinicaltrials.gov ID NCT00813696 ) was performed to compare the combination of cisplatin (P) and G vs. G alone as 1st-line treatment.
  • METHODS: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18-75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B).
  • In Arm B, P 25 mg/m2 weekly (with the exception of day 22) was added to G, same dose used in Arm A (Colucci et al, Cancer 2002; 94:902-10).
  • Median age was 63 yrs (range 35-75), 59% were males, 84% stage IV, 83% KPS≥80.
  • CONCLUSIONS: Weekly combination of P and G, compared to single-agent G as 1st-line treatment of APC, failed to demonstrate any improvement in OS, PFS, ORR and clinical benefit.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ikeda O, Kusunoki S, Kudoh K, Takamori H, Tsuji T, Kanemitsu K, Yamashita Y: Evaluation of the efficacy of combined continuous arterial infusion and systemic chemotherapy for the treatment of advanced pancreatic carcinoma. Cardiovasc Intervent Radiol; 2006 May-Jun;29(3):362-70
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the efficacy of combined continuous arterial infusion and systemic chemotherapy for the treatment of advanced pancreatic carcinoma.
  • PURPOSE: To evaluate the effects of combined continuous transcatheter arterial infusion (CTAI) and systemic chemotherapy in patients with advanced pancreatic carcinoma.
  • METHODS: CTAI was performed in 17 patients with stage IV pancreatic cancer with (n = 11) or without (n = 6) liver metastasis.
  • The inferior pancreatic artery (IPA) was embolized to achieve delivery of the pancreatic blood supply through only the celiac artery.
  • Treatment effects were evaluated based on the primary tumor size, liver metastasis, and survival time and factors such as tumor size, tumor location, and stage of pancreatic carcinoma; the embolized arteries were analyzed with respect to treatment effects and prognosis.
  • The survival time ranged from 4 to 18 months (mean +/- SD, 8.8 +/- 1.5 months).
  • Complete embolization of arteries surrounding the pancreas was achieved in 10 patients; they manifested superior treatment effects and prognoses (p < 0.05).
  • CONCLUSION: In patients with advanced pancreatic cancer, long-term CTAI with systemic chemotherapy appeared to be effective not only against the primary tumor but also against liver metastases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Chemoembolization, Therapeutic / methods. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Angiography. Chi-Square Distribution. Female. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Radiography, Interventional. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16502181.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


24. Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Uchiyama K, Yamaue H: Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol; 2006 May 1;93(6):485-90
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
  • In our study, we investigated whether postoperative chemotherapy improved survival in patients with invasive ductal carcinoma of the pancreas.
  • Between 1987 and 2004, 111 patients underwent pancreatic resection against invasive ductal carcinoma of the pancreas in Wakayama Medical University Hospital.
  • Median survival time (MST) was 19.4 months, 8.6 months, and 7.2 months, in JPS Stage III (UICC Stage IIA and IIB), JPS Stage IVa (UICC Stage IIA and IIB), and JPS Stage IVb (UICC Stage IV), respectively (P < 0.01).
  • The MST of the chemotherapy group was 12 months, and the MST of the non-chemotherapy group was 8.4 months (P < 0.05).
  • Moreover, in JPS Stage IV (UICC Stage IIA, IIB, III, and IV) highly advanced pancreatic cancer, the MST of the chemotherapy group was 10.9 months, and the MST of the group without chemotherapy was 6.6 months (P < 0.01).
  • Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Pancreatectomy / mortality. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16615151.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


25. Mambrini A, Bassi C, Pacetti P, Torri T, Iacono C, Ballardini M, Orlandi M, Guadagni S, Fiorentini G, Cantore M: Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy. Pancreas; 2008 Jan;36(1):56-60
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy.
  • OBJECTIVES: The aim of this study is to identify the prognostic factors of a large group of patients with pancreatic cancer who underwent the same regimen of intra-arterial chemotherapy.
  • RESULTS: Data of 211 patients with advanced pancreatic cancer who underwent FLEC regimen were analyzed.
  • In both univariate and multivariate analyses, pain reduction after treatment (< or =30% of baseline level vs >30%; overall survival, 7.6 vs 11.5 months), stage of disease (III vs IV; overall survival, 10.5 vs 6.6 months), and number of administered cycles (< or =3 vs >3; overall survival, 5.9 vs 12.3 months) were significant and independent predictors of survival.
  • CONCLUSIONS: Pain reduction, stage of disease, and number of administered cycles are independent prognostic factors of overall survival in a multivariate analysis of patients with advanced pancreatic cancer receiving FLEC regimen intra-arterially.
  • [MeSH-major] Adenocarcinoma / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carboplatin / administration & dosage. Carboplatin / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Pain. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18192882.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; BG3F62OND5 / Carboplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEC protocol
  •  go-up   go-down


26. Tomimatsu H, Nakano T: [Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2291-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].
  • We describe two patients, who suffered from Stage IV gastric poorly differentiated adenocarcinoma and underwent palliative total gastrectomy, were treated by sequential chemotherapy and achieved long term-survival.
  • After total gastrectomy, he was treated with methotrexate-5-fluorouracil (MTX/5-FU) sequential therapy for 5 months, S-1 single-agent therapy for 4 years and weekly paclitaxel (PTX) therapy for 9 months.
  • He is being treated with irinotecan (CPT-11) therapy as an outpatient now, and has achieved 5 year 8-month survival.
  • We observed unresectable metastases around the pancreas, aorta, and transverse mesocolon.
  • She was treated with S-1 single-agent therapy for 1 year 10 months, MTX/5-FU sequential therapy for 9 months.
  • She is now receiving weekly PTX therapy for 3 months as an outpatient and has achieved 2 year 11-month survival.
  • [MeSH-major] Adenocarcinoma / therapy. Gastrectomy. Stomach Neoplasms / therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Drug Combinations. Female. Fluorouracil / administration & dosage. Humans. Immunosuppressive Agents / administration & dosage. Male. Methotrexate / administration & dosage. Middle Aged. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079633.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Immunosuppressive Agents; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Meyer F, Lueck A, Hribaschek A, Lippert H, Ridwelski K: Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma. Chemotherapy; 2004 Dec;50(6):289-96
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
  • BACKGROUND: In advanced pancreatic carcinoma, no effective chemotherapy has been found yet due to the lack of appropriate response.
  • Therefore, the hypothesis was that the combination of gemcitabine with other drugs can result in a better outcome of patients.
  • PATIENTS AND METHODS: Twenty-five patients with advanced or metastatic pancreatic carcinoma received combination chemotherapy using gemcitabine and docetaxel in a weekly administration regimen, beginning with 800 mg/m2 of gemcitabine and 25 mg/m2 of docetaxel.
  • Four patients were originally enrolled for each of the seven different dosages of both drugs.
  • Quality of life was evaluated according to the Core Quality of Life Questionnaire (QLQ-C30) of the European Organization for Research and Treatment of Cancer.
  • Main side effects of this combination chemotherapy were gastrointestinal symptoms and hematologic toxicity.
  • CONCLUSION: Combination therapy with gemcitabine and docetaxel in advanced or metastatic pancreatic carcinoma is a well-tolerated and acceptable alternative treatment option with regard to the severity of side effects and its positive impact on quality of life and tumor-associated pain.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Health Status. Humans. Male. Middle Aged. Neoplasm Metastasis. Pain Measurement. Quality of Life. Severity of Illness Index. Taxoids / administration & dosage. Taxoids / adverse effects

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15608445.001).
  • [ISSN] 0009-3157
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


28. Kim SG, Chun JM, Jin R, Kim JY, Won DI, Hwang YJ: Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports. Transplant Proc; 2010 Apr;42(3):843-5
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports.
  • Cancer chemotherapy in chronic hepatitis B virus (HBV) carriers occasionally leads to acute hepatic failure (AHF) from viral reactivation resulting in an high mortality rate.
  • Herein we have reported 2 cases of successful LDLT performed for AHF caused by reactivation of HBV infection during chemotherapy for hematologic malignancies.
  • During 4 cycles of chemotherapy he developed right upper quadrant pain and jaundice.
  • Soon, he developed grade IV hepatic encephalopathy with a total bilirubin level of 50.56 mg/dL and a model for End-Stage Liver Disease score of 40.
  • The patient had been under Imatinib treatment for 1 year until he was admitted for AHF.
  • He developed grade II encephalopathy with a total bilirubin of 50.8 mg/dL.
  • LDLT was a life-saving procedure for AHF caused by reactivation of HBV during chemotherapy for hematologic malignancy.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Benzamides. Carrier State. Disease-Free Survival. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Living Donors. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20430187.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


29. Silberstein E, Walfisch S, Lupu L, Sztarkier I: Twelve-year survival after the diagnosis of locally advanced carcinoma of the pancreas: A case report. J Surg Oncol; 2000 Oct;75(2):142-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twelve-year survival after the diagnosis of locally advanced carcinoma of the pancreas: A case report.
  • The long-term survival rate of patients with carcinoma of the pancreas is low.
  • Even more so, long-term survival of patients with metastatic pancreatic carcinoma is extremely rare.
  • This patient was diagnosed with locoregional carcinoma of the pancreas and therefore underwent gastroenterostomy and cholecystojeojenostomy without resection of the primary tumor.
  • Later he was treated with radiotherapy and chemotherapy and survived 12 years, during 11 of which he had no evidence of disease.
  • He died 12 years after the initial diagnosis from peritoneal dissemination of poorly differentiated carcinoma complicated with obstructive jaundice and sepsis.
  • To our knowledge, this patient had the longest reported survival with locally advanced pancreas carcinoma that was not resected.
  • [MeSH-major] Palliative Care / methods. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Biopsy. Cholangiopancreatography, Endoscopic Retrograde. Combined Modality Therapy. Humans. Immunohistochemistry. Male. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11064396.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


30. Cascinu S, Scartozzi M, Carbonari G, Pierantoni C, Verdecchia L, Mariani C, Squadroni M, Antognoli S, Silva RR, Giampieri R, Berardi R: COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol; 2007 Oct;30(5):526-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
  • OBJECTIVE: The attempt to improve therapeutic results in pancreatic carcinoma has recently focused on the emerging role of molecular biology.
  • We investigated the role of COX-2 and NF-KB expression in relation to the use of a COX-2 inhibitor (celecoxib) associated to gemcitabine and oxaliplatin in pancreatic cancer.
  • METHODS: Forty-four patients with histologically or cytologically verified, locally advanced unresectable and/or metastatic pancreatic carcinoma were eligible for the study.
  • RESULTS: Thirty-three patients (75%) assumed celecoxib for all their treatment period.
  • Treatment was repeated every 2 weeks, until there was evidence of disease progression, patient refusal, or unacceptable toxicity.
  • Efficacy was assessed according to tumor response, clinical benefit, and time-related parameters.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclooxygenase 2 / genetics. Cyclooxygenase 2 Inhibitors / therapeutic use. NF-kappa B / genetics. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Celecoxib. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Patient Selection. Predictive Value of Tests. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17921715.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase 2 Inhibitors; 0 / NF-kappa B; 0 / Organoplatinum Compounds; 0 / Pyrazoles; 0 / Sulfonamides; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


31. Washizawa N, Tokura N, Kase H, Ogawa M, Hattori T, Teramoto T, Kobayashi K, Hirano K: [A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection]. Gan To Kagaku Ryoho; 2000 Nov;27(13):2129-33
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV gastric cancer responding to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection].
  • We treated a case of unresectable gastric cancer in which peritoneal lavage cytology and the primary tumor responded to combined chemotherapy by intravenous, intraarterial and intraperitoneal injection.
  • He underwent laparotomy for gastric cancer in November, 1997.
  • An intraperitoneal catheter was set without gastrectomy because of the unresectability due to extensive peritoneal dissemination and local invasion to pancreas.
  • The patient was given combined chemotherapy using 5-FU 6,000 mg i.v., CDDP 360 mg i.p. and 5-FU 10,500 mg ia by the catheters in the supra vena cava, right gastroepiploic artery and peritoneal cavity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Infusion Pumps, Implantable. Infusions, Intra-Arterial. Infusions, Intravenous. Injections, Intraperitoneal. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasm Invasiveness. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11103247.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


32. Homma H, Doi T, Mezawa S, Takada K, Kukitsu T, Oku T, Akiyama T, Kusakabe T, Miyanishi K, Niitsu Y: A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization. Cancer; 2000 Jul 15;89(2):303-13
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel arterial infusion chemotherapy for the treatment of patients with advanced pancreatic carcinoma after vascular supply distribution via superselective embolization.
  • BACKGROUND: Patients with American Joint Committee on Cancer Stage IV advanced pancreatic carcinoma have been treated by systemic chemotherapy, intraarterial chemotherapy, radiation therapy, and multidisciplinary treatment using a combination of these.
  • In the current study the authors describe the method and results of a new chemotherapy for advanced pancreatic carcinoma.
  • METHODS: To restrict the blood flow into the pancreas (mainly to the great pancreatic artery and the caudal pancreatic artery), the peripancreatic blood vessels were embolized superselectively with microcoils.
  • In 31 patients with advanced pancreatic carcinoma, the catheter tip for the arterial infusion chemotherapy was placed in the splenic artery just proximal to the branching of the great pancreatic artery when the treatment was given for primary tumors, and in the common hepatic artery when the treatment was given for a metastatic liver lesion.
  • RESULTS: Of the 31 patients with advanced pancreatic carcinoma, 23 (74%) underwent hemodynamic change and arterial infusion chemotherapy, with a response rate of 73.9% (complete response rate of 8.7% and a partial response rate of 65.2%) and a mean survival period of 18.26 +/- 10.06 months.
  • CONCLUSIONS: In patients with Stage IV advanced pancreatic carcinoma, arterial infusion chemotherapy after hemodynamic change was found to be effective against both primary tumors and metastatic liver lesions.
  • The authors believe that the treatment presented in the current study should be attempted, even in patients with advanced pancreatic carcinoma, as long as the blood vessels for vascular supply distribution exist.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Ductal, Breast / blood supply. Carcinoma, Ductal, Breast / drug therapy. Embolization, Therapeutic / methods. Pancreatic Neoplasms / blood supply. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Biomarkers, Tumor / analysis. Catheters, Indwelling / adverse effects. Cisplatin / administration & dosage. Disease Progression. Female. Fluorouracil / administration & dosage. Hemodynamics. Hepatic Artery. Humans. Infusions, Intra-Arterial. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Pancreas / blood supply. Splenic Artery

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10918160.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


33. Stathis A, Moore MJ: Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol; 2010 Mar;7(3):163-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced pancreatic carcinoma: current treatment and future challenges.
  • Pancreatic adenocarcinoma is the most lethal of the solid tumors and the fourth leading cause of cancer-related death in North America.
  • Most patients present with locally advanced or metastatic disease that precludes curative resection.
  • In the absence of effective screening methods, considerable efforts have been made during the past decade to identify better systemic treatments.
  • Unfortunately most trials have not shown a survival advantage for most therapies.
  • These preclinical studies revealed many of the molecular mechanisms involved in pancreatic cancer development, which has provided insights into why current therapies are ineffective.
  • These new discoveries provide some optimism that new agents inhibiting specific targets will improve outcome and overcome the resistance of pancreatic cancer to most standard treatments.
  • We review the current standards of care for patients with locally advanced and metastatic pancreatic carcinoma and outline some future directions for the development of new treatment strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20101258.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 83
  •  go-up   go-down


34. Bruell D, Stöcker M, Huhn M, Redding N, Küpper M, Schumacher P, Paetz A, Bruns CJ, Haisma HJ, Fischer R, Finnern R, Barth S: The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. Int J Oncol; 2003 Oct;23(4):1179-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line.
  • Pancreatic carcinoma still has the highest mortality rate in comparison to any other malignancy.
  • Major reasons are late detection of disease, highly aggressive tumor growth and the early formation of metastases.
  • Thus, novel effective therapies are urgently needed to improve the outcome of the patients.
  • Overexpression of the epidermal growth factor receptor (EGFR) and its ligands has been implicated in the oncogenesis of pancreatic carcinoma and associated with an unfavorable prognosis.
  • Binding activity and specificity of the immunotoxin to the EGFR-positive pancreatic carcinoma cell line L3.6pl was confirmed by flow cytometry and ELISA.
  • This is the first report documenting the specific cytotoxicity of a recombinant immunotoxin towards metastatic pancreatic carcinoma cells, suggesting that EGFR-specific antibody toxins may become valuable therapeutic reagents for the treatment of pancreatic carcinoma.
  • [MeSH-major] Carcinoma / drug therapy. Epidermal Growth Factor / chemistry. Immunoglobulin Variable Region / chemistry. Pancreatic Neoplasms / therapy. Recombinant Proteins / chemistry
  • [MeSH-minor] Cell Division. Cell Line, Tumor. Dose-Response Relationship, Drug. Enzyme-Linked Immunosorbent Assay. Escherichia coli / metabolism. Flow Cytometry. Humans. Immunotherapy. Immunotoxins / chemistry. Inhibitory Concentration 50. Ligands. Models, Genetic. Mutation. Neoplasm Metastasis. Plasmids / metabolism. Prognosis. Recombinant Fusion Proteins / chemistry. Single-Chain Antibodies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12964002.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 425(scFv)-ETA'; 0 / Immunoglobulin Variable Region; 0 / Immunotoxins; 0 / Ligands; 0 / Recombinant Fusion Proteins; 0 / Recombinant Proteins; 0 / Single-Chain Antibodies; 0 / scFv 425; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


35. Cascinu S, Frontini L, Labianca R, Catalano V, Barni S, Graiff C, Picone G, Farinati E, Zonato S, Pessi MA, Curti C, Catalano G: A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol; 2000 Oct;11(10):1309-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
  • PATIENTS AND METHODS: Thirty-four patients with histologically verified locally unresectable and/or metastatic pancreatic carcinoma received GEM at the dose of 1,500 mg/m2 with an infusion rate of 10 mg/m2/min, associated to 5-fluorouracil (5-FU) at the dose of 600 mg/m2.
  • Both drugs were administered weekly for two consecutive weeks out of every three weeks.
  • The time to progression was 3.7 months with a median survival of 5.7 months.
  • CONCLUSION: It is unlikely that a fixed dose rate infusion of GEM, at least with this dose, can improve palliation in comparison with the standard 30-min infusion schedule in advanced pancreatic cancer.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11106121.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


36. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, Shields AF: Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer; 2001 Aug 1;92(3):569-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
  • BACKGROUND: Pancreatic carcinoma is considered among the most chemoresistant of human malignancies.
  • Hypothesizing noncross resistance and a synergistic interaction between gemcitabine and cisplatin, early clinical studies have demonstrated significant activity with this combination in patients with several types of malignant disease.
  • A Phase II study was undertaken to determine the efficacy of gemcitabine in combination with cisplatin in patients with locally advanced and metastatic pancreatic carcinoma based on these considerations.
  • METHODS: The eligibility criteria included histologically confirmed, locally advanced, unresectable or metastatic exocrine carcinoma of the pancreas with no prior gemcitabine therapy; prior adjuvant therapy was allowed provided the last day of therapy was at least 6 months prior to starting treatment; clinically measurable or evaluable disease; a Southwest Oncology Group scale performance status of 0-2; a life expectancy of > 12 weeks; and adequate bone marrow, hepatic, and renal function.
  • A total of 42 patients, 4 patients with locally advanced, unresectable disease and 38 patients with metastatic disease, were treated and received a total of 211 cycles of therapy between May 1997 to March 1999.
  • Two additional patients with metastatic disease who achieved major responses to chemotherapy were rendered free of disease surgically, achieving a complete response status.
  • The median time to disease progression was 5.4 months (range, 0.9-20.8 months).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cisplatin / administration & dosage. Cisplatin / adverse effects. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11505401.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-22453
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


37. Kobayashi N, Mizuta M, Otani H, Kubo M, Udaka T, Shirakawa K: [A case of locally advanced gastric cancer responding to pathological CR treated with S-1/CDDP neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1965-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of locally advanced gastric cancer responding to pathological CR treated with S-1/CDDP neoadjuvant chemotherapy].
  • A 75-year-old woman was referred to our hospital because of locally advanced gastric cancer.
  • Gastrointestinal fiberscopy revealed type 3 advanced gastric cancer in the posterior wall of the gastric cardia extending to the middle body.
  • Abdominal CT scan revealed direct invasion of pancreas and regional lymph node metastases, indicating clinical stage IV (cT4N2H0P0M0).
  • After two courses of S-1/CDDP, neoadjuvant chemotherapy was administered, and total gastrectomy with D2 lymphadectomy was performed.
  • Histological examination revealed no residual cancer cells in the surgically obtained stomach and lymph nodes, suggesting a complete pathological response (Grade 3).
  • She was treated with S-1 for one year after operation and presently, 16 months after operation, she is in good health without recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Neoadjuvant Therapy. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Biopsy. Drug Combinations. Female. Humans. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948265.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


38. Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA: In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol; 2005 Aug;56(2):115-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In vitro proliferation assays, and in vivo model studies in metastatic pancreatic carcinoma and subcutaneous xenograft melanoma and small-cell lung carcinoma models.
  • RESULTS: 17-DMAG emerged from screening studies as a potent geldanamycin analog, with the average concentration inhibiting the growth of the NCI anticancer cell line drug screen by 50% being 0.053 microM.
  • "Head to head" comparison with 17-allylamino-17-demethoxygeldanamycin (17-AAG, NSC 330507) revealed 17-DMAG to possess potent activity against certain cell types, e.g., MDA-MB-231 breast carcinoma and HL60-TB leukemia which were relatively insensitive to 17-AAG.
  • 17-DMAG inhibited the growth of the AsPC-1 pancreatic carcinoma xenografts growing as intrahepatic metastases at doses of 6.7-10 mg/kg twice daily for 5 days administered orally under conditions where 17-AAG was without activity.
  • 17-DMAG in an aqueous vehicle at 7.5-15 mg/kg per day for 3 days on days 1-3, 8-10 and 13-17, or 1-5 and 8-12 showed evidence of antitumor activity by the parenteral and oral routes in the MEXF 276 and MEXF 989 melanomas and by the parenteral route in the LXFA 629 and LXFS 650 adenocarcinoma and small-cell carcinoma models.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Melanoma / pathology. Quinones / pharmacology. Skin Neoplasms / pathology
  • [MeSH-minor] Animals. Benzoquinones. Cell Proliferation. Drug Screening Assays, Antitumor. Lactams, Macrocyclic. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / veterinary. Male. Mice. Mice, Nude. Solubility. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791458.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-270; United States / NCI NIH HHS / CM / N01-CM-97017; United States / NCI NIH HHS / CO / N01-CO 12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Lactams, Macrocyclic; 0 / Quinones; 001L2FE0M3 / 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  •  go-up   go-down


39. Oshiro Y, Moon Y, Yamamoto Y, Aita K: [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy]. Gan To Kagaku Ryoho; 2006 May;33(5):667-70
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of stage IV gastric cancer successfully treated with TS-1/CDDP as neoadjuvant chemotherapy].
  • A resected case of gastric cancer is described.
  • The patient was a 60-year-old woman who presented a type 3 gastric tumor complicated by invasion of the head of the pancreas and liver.
  • Radical resection was not indicated, and we administered the following combination chemotherapy with TS-1 and CDDP.
  • 120 mg/day of TS-1 was orally administered for 3 weeks followed by 2 drug-free weeks as 1 course and 9 5 mg (60 mg/m(2)) of CDDP was administered intravenously on day 8.
  • TS-1/CDDP therapy is useful for advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery
  • [MeSH-minor] Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymph Node Excision. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685169.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, Herrmann R: Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol; 2003 Jan 1;21(1):66-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
  • PURPOSE: Preclinical studies indicate positive interactions between capecitabine, an oral fluorouracil precursor, and gemcitabine, the current standard treatment for advanced pancreatic carcinoma (APC).
  • In this study, we investigated the addition of capecitabine to gemcitabine treatment for patients with APC.
  • PATIENTS AND METHODS: This multicenter study included patients naïve to chemotherapy who had histologically or cytologically confirmed, nonresectable or metastatic pancreatic carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12506172.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


41. Fujino Y, Ueda T, Kamigaki T, Takase S, Ajiki T, Kamoda Y, Matsumoto I, Yasuda T, Kuroda Y: Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer. Pancreas; 2007 Apr;34(3):335-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.
  • OBJECTIVES: The prognosis of patients with advanced pancreatic cancer remains very poor.
  • This study was designed to elucidate the prognostic factors of patients with pancreatic cancer to evaluate appropriate treatment with gemcitabine.
  • METHODS: Ninety-nine consecutive patients with stage IV pancreatic cancer were treated in the gemcitabine era at the Kobe University Hospital.
  • Prognostic variables for survival were analyzed (sex, age, performance status, main site of the tumor, tumor size, major vessel invasion, distal metastasis, resection, gemcitabine, radiation, and pathological factors).
  • The Cox proportional hazards model was used to determine the factors influencing the survival of patients with stage IV pancreatic cancer.
  • RESULTS: Multivariate analysis revealed that pancreatic resection, gemcitabine, and distant metastasis significantly influenced the survival of all patients with stage IV pancreatic cancer.
  • Pancreatic resection and gemcitabine were significant factors influencing the survival of patients with stage IVa pancreatic cancer, whereas gemcitabine was the strongest factor influencing stage IVb pancreatic cancer.
  • CONCLUSIONS: Gemcitabine has a possible role for stage IV pancreatic cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414056.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


42. Gordon EM, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Hall FL: First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int J Oncol; 2004 Jan;24(1):177-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
  • Metastatic or non-resectable (stage IV) pancreatic cancer has a rapidly fatal outcome (median survival: 3-6 months), thus making gene therapy a viable therapeutic option.
  • The objectives of the clinical studies are to evaluate the safety/toxicity and potential anti-tumor response/efficacy of intravenous (i.v.) infusions of a 'pathotropic' retroviral vector bearing a cytocidal gene construct (Rexin-G) as a gene transfer intervention for stage IV pancreatic cancer.
  • The encouraging results of this first clinical experience will guide the design and planning of phase I/II clinical trials to establish the safety and efficacy of Rexin-G as the first targeted injectable gene therapy vector for stage IV pancreatic cancer.
  • [MeSH-major] Cyclins / genetics. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclin G. Cyclin G1. Female. Fluorouracil / administration & dosage. Genetic Therapy / methods. Genetic Vectors / administration & dosage. Genetic Vectors / genetics. Hemodynamics / drug effects. Humans. Infusions, Intravenous. Kidney Function Tests. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Pancreas / drug effects. Pancreas / pathology. Pancreas / radiation effects. Retroviridae / genetics. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14654955.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CCNG1 protein, human; 0 / Cyclin G; 0 / Cyclin G1; 0 / Cyclins; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Alldinger I, Tsamaloukas AG, Germing U, Hosch SB, Knoefel WT: Complete remission of a metastatic pancreatic carcinoma after modified G-FLIP therapy. Chemotherapy; 2007;53(5):356-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of a metastatic pancreatic carcinoma after modified G-FLIP therapy.
  • This is a report about a patient who had a complete remission of a metastatic pancreatic adenocarcinoma after a modified G-FLIP therapy administered in an outpatient setting.
  • The administered chemotherapy was very effective and is even more attractive since it could be administered without admission to hospital.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Neoplasm Metastasis / drug therapy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Drug Therapy, Combination. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Recurrence. Time Factors. Tomography Scanners, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17785972.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


44. James E, Waldron-Lynch MG, Saif MW: Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs; 2009 Aug;20(7):634-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
  • A number of studies have shown that the third most common cancer associated with these mutations is pancreatic cancer.
  • There is evidence of in vivo therapeutic response to the cross-linking agents; such as mitomycin C (MMC) in BRCA2 mutated pancreatic cell lines.
  • Our patient presented at the age of 71 years with a dual diagnosis of prostate carcinoma and pancreatic carcinoma on the background of a significant family history of cancer.
  • His current treatment is MMC plus irinotecan as oxaliplatin was removed because of a hypersensitivity reaction.
  • Our case is the first clinical piece of evidence that demonstrates an increased sensitivity to camptothecin-11 and a reduced topoisomerase I relaxation activity in BRCA2 associated pancreatic cancer.
  • This case shows that patients with metastatic pancreatic carcinoma and BRCA2 mutations may have disease that is biologically more chemosensitive and consequently prolong survival despite prognostically unfavorable disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genes, BRCA2. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Resistance, Neoplasm. Genetic Predisposition to Disease. Humans. Male. Neoplasm Metastasis. Survival Rate


45. Starling N, Watkins D, Cunningham D, Thomas J, Webb J, Brown G, Thomas K, Oates J, Chau I: Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J Clin Oncol; 2009 Nov 20;27(33):5499-505
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
  • PURPOSE: This study evaluated safety and efficacy of chemotherapy (gemcitabine plus capecitabine) plus bevacizumab/erlotinib in advanced pancreatic cancer because dual epidermal growth factor receptor/vascular endothelial growth factor blockade has a rational biologic basis in this malignancy.
  • PATIENTS AND METHODS: Patients with untreated, unresectable, locally advanced or metastatic pancreatic carcinoma were enrolled onto one of the following four sequential dose levels (DLs) of escalating capecitabine doses (days 1 to 21): DL1, 910 mg/m(2); DL2, 1,160 mg/m(2); DL3, 1,400 mg/m(2); or DL4, 1,660 mg/m(2).
  • Performance status was 0 and 1 in two and 17 patients, respectively; and nine and 11 patients had locally advanced and metastatic disease, respectively.
  • Median overall and progression-survival times (all patients) were 12.5 and 9.0 months, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Bevacizumab. Capecitabine. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Erlotinib Hydrochloride. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / analogs & derivatives. Follow-Up Studies. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Quinazolines / administration & dosage. Quinazolines / adverse effects. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Nov 20;27(33):5487-91 [19858387.001]
  • (PMID = 19858399.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride; U3P01618RT / Fluorouracil
  •  go-up   go-down


46. Ohta H, Shioji K, Maruyama Y, Watanabe K, Aiba T, Baba Y, Seki K, Yanagi M, Iiri T, Ishizuka K, Isokawa O, Nakamura A, Natsui M, Furukawa K, Suzuki Y, Ban-Nai H, Motoyama N, Mori S, Aoyagi Y: [Gemcitabine treatment in patients with stage IV pancreatic cancer and prognostic factors for survival of patients with stage IVb(a retrospective survey at 15 hospitals in Niigata Prefecture)]. Gan To Kagaku Ryoho; 2008 Dec;35(13):2357-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gemcitabine treatment in patients with stage IV pancreatic cancer and prognostic factors for survival of patients with stage IVb(a retrospective survey at 15 hospitals in Niigata Prefecture)].
  • We performed a retrospective survey at 15 hospitals in Niigata Prefecture to assess the effectiveness of gemcitabine in patients with stage IV pancreatic cancer and to analyze prognostic factors impacting survival in patients with stage IVb.
  • The subjects were 244 unresectable or metastatic pancreatic cancer patients(IVa 68, IVb 176)who were treated with gemcitabine as first-line therapy.
  • The overall response rate was 6.1% and the median survival time(MST)was 194 days.
  • The MST of stage IVa(312 days)was double that of stage IVb(167 days).
  • Prognostic factors for survival of patients with stage IVb were analyzed(performance status, response rate, liver metastasis, peritonitis carcinomatosa, paraaortic lymph node metastasis)with the Cox proportional hazards model.
  • When we compare an effect of other chemotherapy with GEM, we should treat stage IVa and stage IVb separately, and subdivision is necessary for stage IVb.
  • [MeSH-major] Data Collection / statistics & numerical data. Deoxycytidine / analogs & derivatives. Hospitals / statistics & numerical data. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Health Facilities.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19098402.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


47. Horiuchi H, Ishikawa H, Hayashi K, Uchida S, Kodama T, Nishimura K, Ogata T, Yasunaga M, Ohdo M, Hara M, Okuda K, Kinoshita H, Aoyagi S, Shirouzu K: [Chemoradiation therapy for stage IV pancreatic cancer]. Gan To Kagaku Ryoho; 2003 Oct;30(11):1571-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemoradiation therapy for stage IV pancreatic cancer].
  • BACKGROUND: Pancreatic cancer is a malignant tumor with a poor prognosis.
  • It frequently presents with locally advanced and distant metastasis at the time of diagnosis.
  • Favorable results were obtained by performing intraoperative radiation therapy (IORT) and chemotherapy (administration of GEM) for the treatment of inoperable pancreatic cancer.
  • A study was conducted on its efficacy as an adjuvant therapy for inoperable and advanced pancreatic cancer.
  • SUBJECTS AND METHODS: Between May 1998 and December 2002, 40 patients with stage IV pancreatic cancer were treated at our institution.
  • The study comprised background factors, adjuvant therapy and survival rate.
  • RESULTS: According to the treatment modality, the study population was classified into four groups: group A, consisting of 3 patients with localized unresectable tumors who had been treated with IORT: group B, 5 patients who underwent curative resection of primary tumor combined with IORT: group C, 6 patients who were administered GEM combined with IORT: group D, 26 patients not falling into groups A, B or C.
  • In group C, the tumor decreased in size, invasion of large vessels and pancreatic posterior evolution was suppressed, and 4 patients survived for 17 months or more.
  • CONCLUSIONS: Prolongation of the survival period was shown by concomitant IORT and administration of GEM for inoperable advanced pancreatic cancer.
  • Thus, attempting to combine chemotherapy with IORT and giving additional consideration to the administration method was shown to provide adjuvant therapy that can be expected to be effective against stage IV inoperable pancreatic cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Intraoperative Care. Male. Middle Aged. Neoplasm Staging. Pancreatectomy. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14619466.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


48. Lenzi R, Yalcin S, Evans DB, Abbruzzese JL: Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest; 2002;20(4):464-72
Hazardous Substances Data Bank. DIPHENHYDRAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy.
  • In this study, we estimated the response rate, duration of response, and type, severity and reversibility of toxicities in patients with Stage IV adenocarcinoma of the pancreas treated with docetaxel.
  • Twenty-one patients with locally advanced or metastatic pancreatic cancer, previously untreated or treated with surgery or radiation alone, were treated with 100 mg/m2 docetaxel as a 1 hr infusion once every 21 days.
  • The major side effect of the drug was neutropenia, which required a dose reduction to 75 mg/m2 in approximately half of the patients.
  • Docetaxel as a single agent showed limited activity against adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / analogs & derivatives. Paclitaxel / therapeutic use. Pancreatic Neoplasms / drug therapy. Taxoids
  • [MeSH-minor] Adult. Aged. Dexamethasone / administration & dosage. Diphenhydramine / administration & dosage. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12094541.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; 7S5I7G3JQL / Dexamethasone; 8GTS82S83M / Diphenhydramine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


49. Ikeda O, Tamura Y, Nakasone Y, Shiraishi S, Kawanaka K, Tomiguchi S, Yamashita Y, Takamori H, Kanemitsu K, Baba H: Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma. Cardiovasc Intervent Radiol; 2007 Sep-Oct;30(5):912-21
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma.
  • PURPOSE: The purpose of this study was to compare intrahepatic and pancreatic perfusion on fusion images using a combined single-photon emission computed tomography (SPECT)/CT system and to evaluate the efficacy of combined continuous transcatheter arterial infusion (CTAI) and systemic chemotherapy in the treatment of advanced pancreatic carcinoma.
  • MATERIALS AND METHODS: CTAI was performed in 33 patients (22 men, 11 women; age range, 35-77 years; mean age, 60 years) with stage IV pancreatic cancer with liver metastasis.
  • Pancreatic perfusion on fusion images was classified as perfusion presence or as perfusion absent in the pancreatic cancer.
  • Treatment effects were evaluated based on the pancreatic cancer, liver metastasis, and factors such as intrahepatic and pancreatic perfusion on fusion images.
  • RESULTS: On fusion images, pancreatic and intrahepatic perfusion was recorded as hot spot and as homogeneous distribution, respectively, in 18 patients (55%) and as cold spot and heterogeneous distribution, respectively, in 15 (45%).
  • Patients with hot spot in the pancreatic tumor and homogeneous distribution in the liver manifested better treatment results (p < 0.05 and p < 0.01, respectively).
  • Patients with hot spot both in the pancreatic cancer and in the liver survived longer than those with cold spot in the pancreatic cancer and heterogeneous distribution in the liver (median +/- SD, 16.0 +/- 3.7 vs. 8.0 +/- 1.4 months; p < 0.05).
  • CONCLUSIONS: We conclude that in patients with advanced pancreatic cancer, CTAI with systemic chemotherapy appeared to be effective and may prolong their survival.
  • The development of a reservoir port system allowing for the homogeneous distribution of anticancer drugs is necessary to improve the prognosis of patients with advanced pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Pancreatic Ductal / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / therapy. Pancreatic Neoplasms / therapy. Tomography, Emission-Computed, Single-Photon / methods. Tomography, Spiral Computed / methods
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Catheters, Indwelling. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Equipment Design. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Injections, Intravenous. Kaplan-Meier Estimate. Liver Circulation. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Regional Blood Flow. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710478.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


50. Arkosy P, Sasi SL, Enyedi A, Szántó J, András C, Sápy P: [Curative surgical treatment of inoperable pancreatic cancer after neoadjuvant therapy]. Magy Seb; 2005 Feb;58(1):29-33
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Curative surgical treatment of inoperable pancreatic cancer after neoadjuvant therapy].
  • [Transliterated title] Inoperábilis pancreas-carcinoma neo- adjuváns kemoterápiát követo kuratív sebészetének korai tapasztalatai.
  • In the treatment of pancreatic cancer only curative resection increases the life expectancy.
  • At the time of diagnosis most patients are in stage (TMN of pancreatic cancer UICC 1997) III or IV, thus curative resection cannot be performed.
  • Neo-adjuvant therapy shrinks the tumour in 60-70%, giving new hope for the patients.
  • In this paper authors present two cases of pancreatic cancer resections.
  • Palliative operations were performed in patients with inoperable pancreatic cancer.
  • Later neo-adjuvant chemotherapy was performed--in these cases it meant chemotherapy--and after that a second, this time curative procedure was performed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Pancreatectomy. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16018598.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


51. Bartscht T, Sebens T, Gieseler F, Fölsch UR: [A 40-year-old patient with diffuse pain in the lower backbone]. Med Klin (Munich); 2004 Apr 15;99(4):209-12
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] 40-jährige Patientin mit diffusen Schmerzen im Bereich der Lendenwirbelsäule.
  • CASE REPORT: A 40-year-old female patient with pancreatic cancer stage IV and multiple liver metastases is reported.
  • Palliative chemotherapy was performed with gemcitabine monotherapy.
  • CONCLUSION: This case report demonstrates the problems of modern pancreatic cancer therapy.
  • The goals of therapy are cancer control and control of tumor-related symptoms.
  • New agents and the inclusion of tumor biology and mechanism of resistance should result in individual treatment strategies.
  • [MeSH-major] Adenocarcinoma / secondary. Liver Neoplasms / secondary. Low Back Pain / etiology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adult. Biopsy, Needle. Diagnosis, Differential. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Liver / pathology. Palliative Care. Pancreas / pathology. Ultrasonography

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15085290.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Santasusana JM, García López JL, García JJ, Carbonero AI, Plazas JG, Rovira PS, Martos CF, Guzmán MC, Jericó JF, Delgado FJ, Espinosa JC, Muñoz ML, Aguilar EA, Valera JS, García Ribas I, Mena AC: A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD). Clin Transl Oncol; 2005 Dec;7(11):493-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
  • METHODS: Both drugs were administered on days 1, 8 and 15 of every 4 week cycle in chemotherapy-naïve patients with locally advanced unresectable metastatic pancreatic carcinoma.
  • The median progression-free survival (PFS) was 14.4 weeks and the median overall survival (OS) time was 22.7 weeks.
  • CONCLUSIONS: This schedule was not superior in terms of clinical benefit, response rate, PFS and OS than standard gemcitabine treatment
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Follow-Up Studies. Humans. Hyperbilirubinemia / chemically induced. Infusions, Intravenous. Male. Middle Aged. Mucositis / chemically induced. Neutropenia / chemically induced. Patient Compliance. Quality of Life. Spain. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2001 Jun;28(3 Suppl 10):44-9 [11510033.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1267-72 [11106115.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):727-31 [9739438.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1595-8 [10408405.001]
  • [Cites] Ann Oncol. 2001 May;12(5):675-9 [11432627.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1706-13 [11042564.001]
  • [Cites] Eur J Cancer. 1990;26(11-12):1167-256 [2150000.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):97-104 [12488300.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1450-3 [11100374.001]
  • [Cites] Oncology. 2000 Apr;58(3):215-8 [10765123.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1431-9 [12668651.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):585-92 [10080603.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1309-11 [11106121.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Ann Oncol. 1996 Apr;7(4):347-53 [8805925.001]
  • (PMID = 16373060.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. El Kamar FG, Jindal K, Grossbard ML, Mizrachi HH, Kozuch PS: Pancreatic carcinoma with brain metastases: case report and literature review. Dig Liver Dis; 2004 May;36(5):355-60
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic carcinoma with brain metastases: case report and literature review.
  • The case of a patient developing multiple brain metastases from carcinoma of the exocrine pancreas has been described.
  • A 56-year-old man with stage IV pancreatic cancer attained a clinical and radiographic response while receiving the G-FLIP chemotherapy regimen (biweekly gemcitabine, irinotecan, 5-fluorouracil, leucovorin and cisplatin).
  • After 4 months of therapy, he developed gait imbalance and weakness in the right hand.
  • A subsequent biopsy confirmed that these were pancreatic carcinoma metastases.
  • Previously reported cases of brain metastases from pancreatic cancer are reviewed.
  • [MeSH-major] Adenocarcinoma / pathology. Brain Neoplasms / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Fatal Outcome. Humans. Liver Neoplasms / secondary. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15191206.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 26
  •  go-up   go-down


54. Oettle H, Arning M, Pelzer U, Arnold D, Stroszczynski C, Langrehr J, Reitzig P, Kindler M, Herrenberger J, Musch R, Korsten EW, Huhn D, Riess H: A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol; 2000 Oct;11(10):1267-72
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer.
  • BACKGROUND: Gemcitabine (Gemzar) and 5-fluorouracil (5-FU) plus folinic acid (FA) both have proven activity in the treatment of patients with advanced pancreatic cancer.
  • PATIENTS AND METHODS: Thirty-eight patients, median age 60 years (range 34-70) with inoperable, stage IV, pancreatic cancer were enrolled into the study and treated on an outpatient basis.
  • All except one patient received at least one cycle of treatment with gemcitabine (1000 mg/m2), followed by FA (200 mg/m2) and 5-FU (750 mg/m2) administered as a 24-hour continuous infusion on days 1, 8, 15 and 22 of a 42-day schedule.
  • No patient had received prior chemotherapy or radiotherapy.
  • All 38 patients were assessed for efficacy, toxicity and time to progressive disease.
  • The median time to progression was 7.1 months (range 0.4-18.1+; 95% confidence interval (95% CI): 5.3-7.9 months).
  • CONCLUSIONS: The combination of gemcitabine and 5-FU-FA is active and well tolerated and seems to offer an improvement in progression-free interval over both gemcitabine monotherapy and 5-FU-FA therapy.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11106115.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


55. Tazawa K, Matsui K, Morita S, Yoshida T, Shinbo M, Yamagishi F, Yamada A, Tsukada K: [A case of unresectable gastric cancer presenting pylorus stenosis treated orally with S-1 therapy after gastrojejunostomy]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1869-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable gastric cancer presenting pylorus stenosis treated orally with S-1 therapy after gastrojejunostomy].
  • We reported a case of unresectable gastric cancer presenting pylorus stenosis treated orally by S-1 therapy in a 72-year-old man who underwent gastrojejunostomy.
  • Detailed examination showed gastric cancer with pylorus stenosis.
  • The operative findings revealed sT3, sN2, sP1, sH0 and sM1 (metastases of No. 14a lymph nodes invading the super mesenteric artery and pancreas) as an unresectable case with stage IV.
  • After the operation, intake therapy of S-1 was started (80-100 mg/body/dayx28 days).
  • After 2 courses of the therapy, gastrointestinal fiber showed clinically a partial response of the main tumor.
  • After 3 courses of this treatment, the tumor presented multiple liver metastases as a clinically progressive disease state.
  • Paclitaxel therapy was conducted at a dose of 80 mg/body/weekx3 timesx2 courses.
  • The patient had no effective benefits from the treatment and died of the cancer.
  • He had survived 9 months, and the intervals of the intake and home stay were 7.5 months and five months, respectively, after the operation with no side effect of the chemotherapy.
  • Survival was no longer than for patients only operated without S-1 therapy.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Gastric Bypass. Lymph Nodes / pathology. Oxonic Acid / administration & dosage. Pylorus / pathology. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Administration, Oral. Aged. Constriction, Pathologic. Drug Administration Routes. Drug Combinations. Humans. Lymphatic Metastasis. Male. Mesenteric Artery, Superior / pathology. Neoplasm Invasiveness. Pancreatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030027.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


56. Kida Y, Maeshima E, Furukawa K, Ichikawa T, Goda M, Ichinose M: A case of polymyositis with a significantly high level of KL-6 associated with pancreatic cancer. Mod Rheumatol; 2007;17(3):262-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of polymyositis with a significantly high level of KL-6 associated with pancreatic cancer.
  • Abdominal computer tomography findings revealed a pancreatic-tail tumor and multiple liver nodules, diagnosed as primary pancreatic adenocarcinoma with multiple liver metastasis.
  • The stage of the pancreatic cancer was IV, and curative surgery of the tumor was not indicated.
  • Chemotherapy and radiotherapy were administered for the liver metastasis.
  • However, these therapies were ineffective against the tumors.
  • If a high level of KL-6 is found without the increasing activity of lung disease containing interstitial pneumonia in PM patients, examination for the internal malignancies including pancreatic cancer should be performed, although cases of PM with a significantly high level of KL-6 associated with pancreatic cancer are rare.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Polymyositis.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564787.001).
  • [ISSN] 1439-7595
  • [Journal-full-title] Modern rheumatology
  • [ISO-abbreviation] Mod Rheumatol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / Mucins
  •  go-up   go-down


57. de Gramont A, Van Cutsem E: Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology; 2005;69 Suppl 3:46-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
  • Bevacizumab (Avastin) has unprecedented survival benefit in patients with metastatic colorectal cancer.
  • Trials are already in progress to investigate the potential of bevacizumab in indications including metastatic renal cell cancer (RCC), non-small cell lung cancer (NSCLC), pancreatic cancer, breast and ovarian cancer.
  • Bevacizumab offers the potential to increase survival without substantially altering the toxicity profile in these tumor types.
  • Bevacizumab has shown activity in patients with refractory metastatic RCC, where progression-free survival (PFS) was significantly longer in patients treated with bevacizumab (10 mg/kg every 2 weeks) than those treated with placebo (hazard ratio=2.55, p<0.001).
  • In addition, combining bevacizumab with erlotinib (Tarceva) has shown a median time to progression of more than 11 months.
  • In NSCLC, a phase II trial revealed that adding bevacizumab to chemotherapy increased therapeutic benefit compared with chemotherapy alone.
  • Adverse events were mild and easily managed, but six patients receiving bevacizumab developed severe hemoptysis.
  • Adding bevacizumab (10 mg/kg) to the current standard of care, gemcitabine, in stage IV pancreatic cancer has also shown promising efficacy.
  • Several ongoing clinical trials are also studying bevacizumab with various chemotherapy and radiotherapy regimens.
  • Patients given chemotherapy (paclitaxel and carboplatin) plus bevacizumab had a higher response rate, longer PFS and an increase in survival compared with patients on chemotherapy alone.
  • Bevacizumab has also shown activity in patients with metastatic breast cancer.
  • Bevacizumab has the potential to provide significant efficacy benefits for patients with metastatic RCC, NSCLC, pancreatic cancer, and other tumor types when used first line in combination with standard therapy.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Antibodies, Monoclonal / pharmacology. Breast Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Renal Cell / drug therapy. Pancreatic Neoplasms / drug therapy. Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Humans. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy


58. Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT. BioDrugs; 2003;17(3):223-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrin 17 is a growth factor for pancreatic, stomach and colorectal cancers, and a potent stimulator of gastric acid secretion.The anti-gastrin immunogen, G17DT, consists of a large carrier protein, called Diptheria Toxoid (DT).
  • Aphton has entered into an agreement with Aventis Pasteur for the marketing of G17DT in all human cancer indications in North America and Europe.
  • In February 2003, Aphton announced it had received fast track designation for G17DT in combination with cisplatin and fluorouracil for use in stage IV gastric cancer to improve overall survival.
  • In July 2002, the US FDA granted G17DT orphan drug status for the treatment of gastric cancer, an indication that was broader than the indication Aphton originally sought.
  • The vaccine was also granted orphan drug status in Australia for gastric cancer in December 2002.
  • In July 2002, Aphton announced that the US FDA had granted G17DT orphan drug status for the treatment of adenocarcinoma of the pancreas.
  • In September 2002, the US FDA also granted G17DT, used in combination with gemcitabine, fast track status for the treatment of pancreatic cancer patients.
  • In addition, the vaccine was also granted orphan drug status in Australia for pancreatic cancer in December 2002.
  • In March 2003, Aphton announced that the Committee for Orphan Medicinal Products had recommended to the European Commission that G17DT be granted orphan drug status for both pancreatic and gastric cancer in the EU.
  • [MeSH-major] Cancer Vaccines / therapeutic use. Gastrins / antagonists & inhibitors. Vaccines / therapeutic use
  • [MeSH-minor] Animals. Clinical Trials as Topic. Colorectal Neoplasms / immunology. Colorectal Neoplasms / therapy. Humans. Orphan Drug Production. Pancreatic Neoplasms / immunology. Pancreatic Neoplasms / therapy. Peptic Ulcer / immunology. Peptic Ulcer / therapy. Rats. Stomach Neoplasms / immunology. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Immunization.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12749761.001).
  • [ISSN] 1173-8804
  • [Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • [ISO-abbreviation] BioDrugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Gastrins; 0 / Vaccines; 0 / gastrin immunogen; 60748-06-3 / gastrin 17
  • [Number-of-references] 15
  •  go-up   go-down


59. Nagaie T, Morita M, Nakagawa M, Itoh S, Aikawa M, Yagi S, Wakiyama S, Kitte T, Shimotakahara A, Kawaguchi A, Wada H, Nakanishi K, Kihara K, Koyanagi N: [A remarkably improved multimetastatic gastric cancer with the use of TS-1 and CDDP]. Gan To Kagaku Ryoho; 2001 Dec;28(13):2069-72
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A remarkably improved multimetastatic gastric cancer with the use of TS-1 and CDDP].
  • On the abdominal ultrasound and abdominal CT, there was evidence of multiple, massive liver metastases with dilatation of intrahepatic bile ducts, thickened wall of the stomach from the body to the antrum, direct invasion to the pancreas, multiple lymph node metastases, and ascites.
  • We believed it was Stage IV and too far advanced for surgery.
  • Therefore, ST-1 60 mg bid was started, and CDDP 50 mg was infused in the seventh week.
  • On the follow-up CT and ultrasound three months later, the thickening of the gastric wall and the lymph node metastasis had improved and the border between the stomach and the pancreas had become clearer.
  • No side effects were evident during the treatment with the medications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Antimetabolites, Antineoplastic / administration & dosage. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Combinations. Humans. Male. Middle Aged. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Quality of Life. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11791387.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


60. Nakamura H, Katayose Y, Rikiyama T, Onogawa T, Yamamoto K, Yoshida H, Hayashi H, Ohtsuka H, Hayashi Y, Egawa S, Unno M: Advanced bile duct carcinoma in a 15-year-old patient with pancreaticobiliary maljunction and congenital biliary cystic disease. J Hepatobiliary Pancreat Surg; 2008;15(5):554-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced bile duct carcinoma in a 15-year-old patient with pancreaticobiliary maljunction and congenital biliary cystic disease.
  • We report a case of advanced bile duct carcinoma arising in a 15-year-old female with pancreaticobiliary maljunction and congenital biliary cystic disease.
  • Surgical and histopathological findings indicated advanced tubular adenocarcinoma, classified as final stage IVb according to the General rules for surgical and pathological studies on cancer of the biliary tract proposed by the Japanese Society of Biliary Surgery, 5th edition, and stage IV according to the American Joint Committee on Cancer (AJCC)/International Union Against Cancer (UICC), 6th edition.
  • She underwent chemotherapy with gemcitabine HCl after discharge.
  • Although it is well known that biliary malignancies arise frequently in patients with pancreaticobiliary maljunction, it is uncommon for advanced bile duct carcinoma to occur in a 15-year-old female.
  • [MeSH-minor] Adolescent. Biliary Tract / abnormalities. Cysts / congenital. Female. Hepatectomy. Humans. Pancreas / abnormalities. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Digestive Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836813.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


61. Boadas J, Balart J, Capellà G, Lluís F, Farré A: Survival of cancer of the pancreas. Bases for new strategies in diagnosis and therapy. Rev Esp Enferm Dig; 2000 May;92(5):316-25
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of cancer of the pancreas. Bases for new strategies in diagnosis and therapy.
  • OBJECTIVE: The ominous prognosis of pancreatic carcinoma (PC) has led to a nihilistic attitude among physicians, and to the need to develop better tools for diagnosis, staging and treatment.
  • The aim of this study was to analyze a series of patients with PC in order to determine stage-related survival, and to try to improve diagnostic and therapeutic strategies.
  • TNM stage and survival were calculated.
  • We also analyzed age, sex, time elapsed until diagnosis, diagnostic tests, size and location, cytologic pathology confirmation, number of patients undergoing surgery, and procedures used.
  • Time elapsed until diagnosis: 3 +/- 15.7 months.
  • TNM staging: stage I 13%; stage II 25%; stage III 20%; stage IV 42%.
  • Stage-related survival: stage I 14 months; stage II 6 months; stage III 4 months; stage IV 1 month.
  • In 55% of the patients surgery revealed a higher stage of disease than had been diagnosed preoperatively.
  • CONCLUSIONS: Diagnosis was made at a late stage in many patients.
  • Early diagnosis, preoperative staging and postoperative management should be improved in these patients, and surgery should be associated with complementary chemotherapy and/or radiotherapy.
  • [MeSH-major] Pancreatic Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10927931.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] SPAIN
  •  go-up   go-down


62. Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D: Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol; 2009 Apr;32(2):115-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy.
  • OBJECTIVE: To evaluate the toxicity of daily gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor, with concurrent chemoradiation (CRT) in patients with locally advanced pancreatic adenocarcinoma and prospectively evaluate plasma k-ras as a potential marker of response to gefitinib and CRT.
  • Patients received 50.4 Gy/28 fractions of external beam radiation with weekly paclitaxel (40 mg/m IV) followed by maintenance on gefitinib.
  • Plasma k-ras codon 12 mutations were detected using a two-stage restriction fragment length polymorphism-polymerase chain reaction assay on patients' plasma both before and after therapy.
  • Three patients did not complete therapy, only one was possibly associated with study drug.
  • K-ras mutations were detected in the pre-gefitinib plasma of 5/11 patients and in the matched tumor tissue of 3/4 patients.
  • In patients where k-ras mutations were undetectable post-treatment, survival times were favorable.
  • CONCLUSIONS: Combination of daily gefitinib with concurrent CRT in this locally advanced pancreatic cancer population was reasonably tolerated.
  • Rapid changes in serum k-ras may provide critical information as to the efficacy of a novel agent and assist in tailoring treatment for cancers of the pancreas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Mutation / genetics. Pancreatic Neoplasms / therapy. Proto-Oncogene Proteins / blood. Radiotherapy, Conformal. ras Proteins / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Aged. Combined Modality Therapy. DNA Mutational Analysis. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length. Prognosis. Prospective Studies. Quinazolines / administration & dosage. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307945.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; EC 3.6.5.2 / ras Proteins; P88XT4IS4D / Paclitaxel; S65743JHBS / gefitinib
  •  go-up   go-down


63. Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G: Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol; 2010 Oct;33(5):461-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.
  • BACKGROUND: Patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy are still in relatively good clinical conditions and may still require second-line chemotherapy, which is frequently administered in daily clinical practice given to without solid scientific support.
  • PATIENTS AND METHODS: A retrospective survey was carried out including 40 patients with stage III or IV gemcitabine-refractory pancreatic carcinoma.
  • Response evaluation criteria in solid tumors and National Cancer Institute common toxicity criteria were employed respectively for response and toxicity assessment.
  • The median time to progression was 3.7 (range, 1-6.5 months), and median overall survival was 6 months (range, 2-8.2 months).
  • A stabilization of performance status and a subjective improvement of cancer-related symptoms were recorded in 21 patients (52.5%).
  • No correlation has been found between length of time to progression during first-line chemotherapy and length of that reported in the second-line setting or objective response.
  • CONCLUSIONS: Data presented in this article demonstrate that the second-line FOLFIRI regimen are able to induce an objective response in a relatively small fraction of patients with gemcitabine-refractory adenocarcinoma of the pancreas.
  • The use of second-line chemotherapy should be carefully proposed to patients with good performance status or those who had a good response to first-line therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Drug-Related Side Effects and Adverse Reactions. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20142727.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


64. Koizumi M, Sata N, Shimura K, Tsukahara M, Yoshizawa K, Kurihara K, Hyodo M, Yasuda Y, Nagai H: [An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2133-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)].
  • A 76-year-old man developed jaundice and was hospitalized in January 2002.
  • A 3 cm tumor was found in the head of the pancreas by abdominal CT, and the patient underwent laparotomy.
  • The tumor was histologically diagnosed as a well-differentiated adenocarcinoma, and showed extensive invasion to the portal vein (T4NXM 0 Stage IV a).
  • On the basis of a drug sensitivity test, chemotherapy with 800 mg/m2/week gemcitabine was administered.
  • The patient showed prolonged NC without any symptoms for 22 months, although the CEA and DUPAN-2 levels gradually increased during this time and massive ascites were detected in a routine abdominal CT at 22 months postsurgery.
  • The patient died after 25 months of chemotherapy.
  • Here we report a case of unresectable pancreatic cancer treated with gemcitabine on the basis of a drug sensitivity test.
  • [MeSH-major] Adenocarcinoma / drug therapy. Ambulatory Care. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Screening Assays, Antitumor. Humans. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352944.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


65. Saif MW, Sviglin H, Carpenter M: Impact of ethnicity on outcome in pancreatic carcinoma. JOP; 2005 May;6(3):246-54
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of ethnicity on outcome in pancreatic carcinoma.
  • In pancreatic cancer, African Americans are thought to have a higher incidence and poorer prognosis than Whites.
  • PATIENTS: A total 645 pancreatic cancer patients were identified in the database, of which, 530 patients were eligible for this study and retained for the statistical analysis.
  • Overall, 132 patients out of 415 (31.8%) were seen in stage I, 61 (14.7%) in stage II, 105 (25.3%) in stage III, 117 (28.2%) in stage IV, while 115 patients (21.7%) had missing stage.
  • Overall, 125 (23.6%) received surgery alone, 54 (10.2%) surgery with chemotherapy, 5 (0.9%) surgery with external radiation therapy, 10 (1.9%) external radiation therapy alone, 68 (12.8%) chemotherapy alone, 58 (10.9%) chemo-external radiation therapy, and 210 (39.6%) no therapy.
  • There were more survivors in females (43/255, 16.9%) than in males (25/275, 9.1%; P=0.009), and females had significantly greater survival times as compared to males (P=0.022).
  • CONCLUSIONS: Pancreatic cancer is a disease of both ethnicities with a slight male predominance among Whites and female predominance among Blacks.
  • We did not find any significant difference in the treatment specific outcome and survival between Blacks and Whites.
  • [MeSH-major] Adenocarcinoma / ethnology. Adenocarcinoma / therapy. African Americans. European Continental Ancestry Group. Pancreatic Neoplasms / ethnology. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Data Interpretation, Statistical. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Sex Characteristics. Survival Rate. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - African American Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15883475.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


66. Levy BF, Karanjia ND, Whitaker SJ: Long-term survival with stage IV poorly differentiated pancreatic adenocarcinoma. HPB (Oxford); 2004;6(2):123-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival with stage IV poorly differentiated pancreatic adenocarcinoma.
  • BACKGROUND: Metastatic poorly differentiated adenocarcinoma of the pancreas has a poor outcome despite the use of various chemotherapy regimes.
  • Computed tomography (CT) showed a large tumour in the head and body of pancreas, and needle biopsy confirmed a poorly differentiated adenocarcinoma.
  • DISCUSSION: Previous studies using numerous chemotherapy regimes have not significantly altered the outcome of pancreatic cancer.
  • To the best of our knowledge this is the longest surviving case of a patient with advanced metastatic adenocarcinoma (stage IV) of the pancreas treated with chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2002 Jan;167(1):16-20 [11743265.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):875-8 [11462946.001]
  • [Cites] J Urol. 2001 Feb;165(2):509-10 [11176409.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1499-503 [11677995.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):491-4 [10027318.001]
  • [Cites] Oncology. 2001;60(1):8-18 [11150902.001]
  • (PMID = 18333063.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2020660
  •  go-up   go-down


67. Alsamarai S, Zergebel C, Zhang J, Furuie T, Urrea PD, Saif MW: Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer. JOP; 2008;9(2):185-91
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer.
  • CONTEXT: Pancreatic cancer is the third most common gastrointestinal malignancy in the United States.
  • Due to difficulty in diagnosis, 40% of patients are stage IV by the time of diagnosis and median survival is only four to six months.
  • Current therapy for advanced pancreatic cancer focuses largely on gemcitabine.
  • However, a relatively new drug, S-1, is showing promising results.
  • Phase II studies of S-1 monotherapy and recent combination with gemcitabine were conducted for the treatment of metastatic pancreatic cancer.
  • CASE REPORT: We report a 68-year-old man who presented with stage IIB pancreatic cancer which advanced to stage IV after undergoing a Whipple procedure and adjuvant treatment with gemcitabine.
  • The patient was refractory to treatment with gemcitabine as well as irinotecan, taxotere, and cetuximab.
  • He subsequently participated in a trial involving the drug S-1.
  • He achieved 10-month survival with preserved quality of life: he had 14 cycles of S-1 and maintained an ECOG performance status of 0-1 throughout.
  • CONCLUSION: For this patient, 14 cycles of S-1 were well-tolerated for 10 months after failing two prior chemotherapeutic regimens suggesting important insight that S-1 may be active and convenient for its oral use and it may have favorable safety profile in patients with metastatic pancreatic cancer.
  • Randomized trials are warranted to determine the effectiveness of S-1 for the treatment of pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Oxonic Acid / administration & dosage. Pancreatic Neoplasms / drug therapy. Tegafur / administration & dosage
  • [MeSH-minor] Aged. Drug Combinations. Humans. Male. Pancreas / pathology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18326927.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


68. Stemmler J, Stieber P, Szymala AM, Schalhorn A, Schermuly MM, Wilkowski R, Helmberger T, Lamerz R, Stoffregen C, Niebler K, Garbrecht M, Heinemann V: Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie; 2003 Oct;26(5):462-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
  • BACKGROUND: Serial kinetics of serum CA 19-9 levels have been reported to reflect response and survival in patients with pancreatic cancer undergoing surgery, radiotherapy, and chemotherapy.
  • We prospectively studied serial kinetics of serum CA 19-9 levels of patients with locally advanced or metastatic disease treated with gemcitabine and cisplatin.
  • PATIENTS AND METHODS: Enrolled in the study were 87 patients (female/male = 26/61; stage III/IV disease = 24/63).
  • Serum samples were collected at the onset of chemotherapy and before the start of a new treatment cycle (day 28).
  • 43 (55.8%) patients were CA 19-9 responders, defined by a > or = 50% decrease in CA 19-9 serum levels within 2 months after treatment initiation.
  • CONCLUSION: CA 19-9 kinetics in serum serve as an early and reliable indicator of response and help to predict survival in patients with advanced pancreatic cancer receiving effective treatment with gemcitabine and cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Pancreas / pathology. Prognosis. Survival Rate. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger GmbH, Freiburg
  • (PMID = 14605463.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


69. Zou YP, Li WM, Zheng F, Li FC, Huang H, Du JD, Liu HR: Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol; 2010 Oct 28;16(40):5104-10
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer.
  • AIM: To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with (125)iodine seed implantation for unresectable pancreatic cancer.
  • METHODS: Thirty-two patients (21 males and 11 females) at the age of 68 years (range 48-90 years) with unresectable locally advanced pancreatic cancer admitted to our hospital from January 2006 to May 2008 were enrolled in this study.
  • The tumor, 4-12 cm in diameter, located in pancreatic head of 23 patients and in pancreatic body and tail of 9 patients, was found to be unresectable during operation.
  • Diagnosis of pancreatic cancer was made through intraoperative biopsy.
  • In brief, a RFA needle was placed, which was confirmed by intraoperative ultrasound to decrease the potential injury of surrounding vital structures, a (125)iodine seed was implanted near the blood vessels and around the tumor border followed by bypass palliative procedure (cholangio-jejunostomy and/or gastrojejunostomy) in 29 patients.
  • The pain score on day 7 after operation, 1 and 3 mo after combined therapy was decreased from 5.86 ± 1.92 before operation to 2.65 ± 1.04, 1.65 ± 0.88 and 2.03 ± 1.16, respectively, after operation (P < 0.05).
  • The rate of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) in 32 patients was 21.8% (7/32), 56.3% (18/32), 15.6% (5/32) and 6.3% (2/32), respectively, 6 mo after operation, with a median overall survival time of 17. 5 mo.
  • The median survival time of patients at stage III was longer than that of those at stage IV (19 mo vs 10 mo, P = 0.0026).
  • The median survival time of patients who received and did not receive chemotherapy after operation was 20 mo and 16 mo, respectively (P = 0.0176).
  • All the patients recovered well after conservative support treatment.
  • CONCLUSION: Intraoperative RFA combined with (125)iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage III.
  • [MeSH-major] Adenocarcinoma / therapy. Catheter Ablation / methods. Iodine Radioisotopes / therapeutic use. Pancreatic Neoplasms / therapy. Radiotherapy / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Feb 1;97(3):554-60 [12548596.001]
  • [Cites] Breast Cancer. 2003;10(1):4-9 [12525756.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1346-52 [12599244.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):85-7 [14736529.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2004 Apr;28(3):219-30 [15084961.001]
  • [Cites] Lancet. 1974 Nov 9;2(7889):1127-31 [4139420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):931-5 [2808054.001]
  • [Cites] Ann Surg. 1990 Aug;212(2):132-9 [1695834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):305-11 [1587751.001]
  • [Cites] Lifetime Data Anal. 1999;5(1):81-90 [10214004.001]
  • [Cites] Gastrointest Endosc. 1999 Sep;50(3):392-401 [10462663.001]
  • [Cites] Minim Invasive Neurosurg. 2004 Dec;47(6):325-8 [15674746.001]
  • [Cites] Clin Liver Dis. 2005 May;9(2):301-14, viii [15831275.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1281-92 [16001679.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50 [16029791.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):657-66 [16111466.001]
  • [Cites] Invest Radiol. 2005 Sep;40(9):583-90 [16118551.001]
  • [Cites] Prostate. 2005 Nov 1;65(3):260-7 [16015591.001]
  • [Cites] Eur J Radiol. 2005 Dec;56(3):403-8 [15964164.001]
  • [Cites] JOP. 2006;7(1):1-4 [16407612.001]
  • [Cites] JOP. 2006;7(1):74-8 [16407624.001]
  • [Cites] J Surg Oncol. 2006 May 1;93(6):485-90 [16615151.001]
  • [Cites] Langenbecks Arch Surg. 2007 Jan;392(1):55-60 [17089173.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Semin Oncol. 2007 Aug;34(4):327-34 [17674961.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1224-30 [18381371.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5513-8 [19858379.001]
  • [Cites] Pancreas. 2000 Jan;20(1):14-20 [10630378.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):332-5 [10722037.001]
  • [Cites] Acta Chir Iugosl. 2002;49(3):19-24 [12587443.001]
  • (PMID = 20976848.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  • [Other-IDs] NLM/ PMC2965288
  •  go-up   go-down


70. McKenzie S, Mailey B, Artinyan A, Kim J, Ellenhorn JD: The incidence and outcomes of pancreatectomy in patients with metastatic pancreatic adenocarcinoma. JOP; 2010;11(4):341-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence and outcomes of pancreatectomy in patients with metastatic pancreatic adenocarcinoma.
  • CONTEXT: Despite current management guidelines, patients with metastatic pancreatic cancer continue to undergo pancreatic resection.
  • OBJECTIVE: Our objective was to determine the incidence and outcomes of pancreatic resection in the setting of known metastatic disease.
  • DESIGN: Using the Los Angeles County Cancer Surveillance Program, patients with pancreatic adenocarcinoma who underwent pancreatic resection with known M1 (AJCC stage IV) metastatic disease between the years 1988-2006 were assessed.
  • PATIENTS: Patients with biopsy proven M1 pancreatic adenocarcinoma.
  • INTERVENTIONS: Pancreatic resection, systemic chemotherapy, radiation therapy.
  • RESULTS: Of 8,549 patients with pancreatic adenocarcinoma from Cancer Surveillance Program, 54% (n=4,649) initially presented with M1 disease.
  • Within this M1 cohort, 2% (n=92) of patients underwent pancreatic resection and formed our final study cohort; these patients comprised 7% of the overall number of pancreatic resections performed for pancreatic adenocarcinoma during the study period.
  • Only 35% (n=32) of the study cohort received adjuvant chemotherapy; and 13% (n=12) received adjuvant radiotherapy.
  • Surgery provided no survival benefit over chemotherapy in patients with M1 disease and was associated with an 18% 30-day mortality.
  • CONCLUSION: A large number of patients from Los Angeles County have undergone pancreatic resection despite the presence of known metastatic disease.
  • Patient survival remains abysmal in this setting and these results are likely a microcosm of the surgical management of metastatic pancreatic cancer in the USA.
  • These results highlight the necessary efforts to maintain appropriate standards of care in the management of pancreatic cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / surgery. Pancreatectomy / statistics & numerical data. Pancreatic Neoplasms / epidemiology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601808.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


71. Hall IE, Andersen MS, Krumholz HM, Gross CP: Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol; 2009;2009:182521
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is uncertainty about risk heterogeneity for venous thromboembolism (VTE) in older patients with advanced cancer and whether patients can be stratified according to VTE risk.
  • We performed a retrospective cohort study of the linked Medicare-Surveillance, Epidemiology, and End Results cancer registry in older patients with advanced cancer of lung, breast, colon, prostate, or pancreas diagnosed between 1995-1999.
  • We used survival analysis with demographics, comorbidities, and tumor characteristics/treatment as independent variables.
  • Outcome was VTE diagnosed at least one month after cancer diagnosis.
  • Compared to prostate cancer (1.4 VTEs/100 person-years), there was marked variability in VTE risk (hazard ratio (HR) for male-colon cancer 3.73 (95% CI 2.1-6.62), female-colon cancer HR 6.6 (3.83-11.38), up to female-pancreas cancer HR 21.57 (12.21-38.09).
  • Stage IV cancer and chemotherapy resulted in higher risk (HRs 1.75 (1.44-2.12) and 1.31 (1.0-1.57), resp.).
  • Stratifying the cohort by cancer type and stage using recursive partitioning analysis yielded five groups of VTE rates (nonlocalized prostate cancer 1.4 VTEs/100 person-years, to nonlocalized pancreatic cancer 17.4 VTEs/100 patient-years).
  • In a high-risk population with advanced cancer, substantial variability in VTE risk exists, with notable differences according to cancer type and stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Feb 11;318(6):352-5 [3123929.001]
  • [Cites] Blood. 2008 May 15;111(10):4902-7 [18216292.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):677-81 [8594425.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):682-7 [8594426.001]
  • [Cites] Am J Hematol. 1996 Apr;51(4):319-23 [8602634.001]
  • [Cites] Ann Intern Med. 1996 Jul 1;125(1):1-7 [8644983.001]
  • [Cites] N Engl J Med. 1997 Sep 4;337(10):663-9 [9278462.001]
  • [Cites] Health Econ. 1994 Nov-Dec;3(6):385-93 [9435921.001]
  • [Cites] Arch Intern Med. 1998 Sep 14;158(16):1809-12 [9738611.001]
  • [Cites] Circulation. 1999 Mar 16;99(10):1325-30 [10077516.001]
  • [Cites] Chest. 1999 Apr;115(4):972-9 [10208194.001]
  • [Cites] N Engl J Med. 1999 Sep 9;341(11):793-800 [10477777.001]
  • [Cites] Medicine (Baltimore). 1999 Sep;78(5):285-91 [10499070.001]
  • [Cites] Ann Intern Med. 2000 Mar 21;132(6):425-34 [10733441.001]
  • [Cites] N Engl J Med. 2000 Dec 21;343(25):1846-50 [11117976.001]
  • [Cites] J Clin Epidemiol. 2000 Dec;53(12):1258-67 [11146273.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3712-8 [11533092.001]
  • [Cites] Curr Opin Pulm Med. 2001 Sep;7(5):360-4 [11584190.001]
  • [Cites] Med Care. 2002 Mar;40(3):201-11 [11880793.001]
  • [Cites] Thromb Haemost. 2002 Apr;87(4):575-9 [12008937.001]
  • [Cites] Arch Intern Med. 2002 Jun 10;162(11):1245-8 [12038942.001]
  • [Cites] Thromb Haemost. 2002 Jun;87(6):1076-7 [12083490.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):4015-21 [12351599.001]
  • [Cites] Thromb Haemost. 2002 Nov;88(5):745-9 [12428088.001]
  • [Cites] N Engl J Med. 2003 Apr 10;348(15):1425-34 [12601075.001]
  • [Cites] Thromb Haemost. 2003 Mar;89(3):493-8 [12624633.001]
  • [Cites] Arch Intern Med. 2003 Mar 24;163(6):688-92 [12639201.001]
  • [Cites] Semin Thromb Hemost. 2003 Jun;29(3):247-58 [12888929.001]
  • [Cites] J Thromb Haemost. 2003 Dec;1(12):2463-5 [14675077.001]
  • [Cites] Thromb Res. 2003;112(4):203-7 [14987912.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1944-8 [15143088.001]
  • [Cites] Am J Med. 2004 Jul 1;117(1):19-25 [15210384.001]
  • [Cites] Circulation. 2004 Aug 17;110(7):874-9 [15289368.001]
  • [Cites] Chest. 2004 Sep;126(3 Suppl):338S-400S [15383478.001]
  • [Cites] J Clin Pathol. 2004 Dec;57(12):1254-7 [15563663.001]
  • [Cites] Thromb Haemost. 2005 Jan;93(1):76-9 [15630494.001]
  • [Cites] JAMA. 2005 Feb 9;293(6):715-22 [15701913.001]
  • [Cites] Thromb Haemost. 2005 Feb;93(2):284-8 [15711744.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):297-303 [16282243.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):289-96 [16317012.001]
  • [Cites] Arch Intern Med. 2006 Feb 27;166(4):458-64 [16505267.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1112-8 [16505431.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Sep;59(3):211-7 [16806961.001]
  • [Cites] Eur Heart J. 2006 Aug;27(16):1954-64 [16847008.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):70-6 [17194906.001]
  • [Cites] J Gen Intern Med. 2007 Mar;22(3):321-6 [17356962.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2339-46 [17918266.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2119-52 [17939129.001]
  • [Cites] J Thromb Haemost. 2008 Apr;6(4):601-8 [18208538.001]
  • [Cites] Med Care. 1993 Aug;31(8):732-48 [8336512.001]
  • (PMID = 20445797.001).
  • [ISSN] 1687-8566
  • [Journal-full-title] Journal of cancer epidemiology
  • [ISO-abbreviation] J Cancer Epidemiol
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / K08 AG024842
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2859683
  •  go-up   go-down


72. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F, Gruppo Oncologico Italia Meridionale (GOIM), Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD), Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC): Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol; 2010 Apr 1;28(10):1645-51
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
  • PURPOSE: Single-agent gemcitabine became standard first-line treatment for advanced pancreatic cancer after demonstration of superiority compared with fluorouracil.
  • The Gruppo Italiano Pancreas 1 randomized phase III trial aimed to compare gemcitabine plus cisplatin versus gemcitabine alone (ClinicalTrials.gov ID NCT00813696).
  • PATIENTS AND METHODS: Patients with locally advanced or metastatic pancreatic cancer, age 18 to 75 years, and Karnofsky performance status (KPS) > or = 50, were randomly assigned to receive gemcitabine (arm A) or gemcitabine plus cisplatin (arm B).
  • Median age was 63, 59% were male, 84% had stage IV, and 83% had KPS > or = 80.
  • Combination therapy produced more hematologic toxicity, without relevant differences in nonhematologic toxicity.
  • CONCLUSION: The addition of weekly cisplatin to gemcitabine failed to demonstrate any improvement as first-line treatment of advanced pancreatic cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20194854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00813696
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


73. Diaconu C, Mateescu D, Bălăceanu A, Marcu M, Jianu V, Stănică A: Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report. J Med Life; 2010 Jan-Mar;3(1):96-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer presenting with paraneoplastic thrombophlebitis--case report.
  • CONTEXT: The complex of symptoms in pancreatic cancer is vague, which often delays presentation and diagnosis.
  • Thrombophlebitis is an unusual presentation of pancreatic cancer, which appears more frequent in the cancer of the body and tail of the pancreas.
  • The head of the pancreas was normal, the body and the tail could not be seen very well due to flatulence.
  • After computed tomography, the diagnosis was "Pancreatic tumor with multiple hepatic metastases (stage IV)".
  • At the end of the seventh month of treatment, the patient suffered an irreversible ischemic cardiac event.
  • CONCLUSION: Superficial thrombophlebitis can be the initial manifestation of the pancreatic cancer.
  • Gemcitabine and erlotinib is now a FDA approved regimen for patients with metastatic pancreatic cancer.
  • While the search for the best gemcitabine based backbone for advanced pancreatic cancer continues, studies of anti-angiogenic agents alone or in combination with traditional chemotherapy, should be undertaken, as they may improve overall survival in this group of poor prognosis patients.
  • [MeSH-major] Pancreatic Neoplasms / drug therapy. Paraneoplastic Syndromes / etiology. Thrombophlebitis / etiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5235-46 [16051966.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1425-33 [16012181.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):8033-40 [16258101.001]
  • (PMID = 20302205.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Quinazolines; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC3019029
  •  go-up   go-down


74. Sumii T, Funakoshi A, Ito T, Mizumoto K, Tanaka M, Migita Y, Sakai T, Shinozaki H, Yamaguchi H, Niyahara T, Muranaka T, Eriguchi N, Ueki T, Fukuoka Pancreatic Cancer Chemotherapy Group: [Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer]. Gan To Kagaku Ryoho; 2003 Jul;30(7):971-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].
  • Forty-nine patients with unresectable pancreatic cancer (stage IV disease) received gemcitabine in a multi-center trial in the Fukuoka pancreatic cancer chemotherapy group, Japan.
  • These results suggested that gemcitabine is currently a first-line therapeutic agent for advanced pancreatic cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Administration Schedule. Exanthema / chemically induced. Female. Humans. Karnofsky Performance Status. Male. Middle Aged. Nausea / chemically induced. Neutropenia / chemically induced. Survival Rate. Vomiting, Anticipatory / etiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12894712.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


75. Wu J, Shao Y, Rong W, Shan Y, Gao J, Wu T: [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas]. Zhonghua Zhong Liu Za Zhi; 2002 Sep;24(5):497-500
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of 178 patients with carcinoma of the head of pancreas].
  • OBJECTIVE: To improve the diagnosis and treatment of carcinoma of head of pancreas.
  • METHODS: A retrospective study was carried out to evaluate 178 patients suffering from carcinoma of head of pancreas.
  • RESULTS: Pain in the epigastrium and obstructive jaundice were observed in 70% and 74.2% of these 178 patients, both of which were of significance (P < 0.001) between stage I, II and stage III, IV disease.
  • Only 18% of patients had pain in the back, 81.3% of whom belonged to the stage IV category.
  • The detection rate of the tumor by B-ultrasound, CT and MRI were 74.2%, 87.3% and 85.5%, respectively.
  • The median survival time was 7 months in patients with unresectable tumor who received radiotherapy and/or chemotherapy.
  • By now, pancreaticoduodenectomy is still the only effective treatment for the carcinoma of head of pancreas and internal drainage is an important palliative measure.
  • [MeSH-major] Pain / etiology. Pancreatic Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hyperglycemia / etiology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12485509.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


76. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, Um SH, Kim JS, Kim YH: Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol; 2000 Aug;23(4):425-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
  • Adenocarcinomas of the pancreas and biliary tract are highly malignant neoplasms, which are found in the advanced stage.
  • Chemotherapy commonly plays a palliative role in the treatment of pancreatic and biliary tract cancers.
  • Recently, some reports presented interesting results, in which 5-FU, modulated with levofolinic acid (leucovorin), was active in patients with colorectal cancer.
  • In relation, we performed a phase II study of 5-FU, modulated with leucovorin, in patients affected by advanced pancreatic or biliary tract cancer.
  • Fifty-one patients with nonresectable carcinomas of the pancreas or biliary tract admitted to Korea University Hospital between May 1995 and December 1998 were included in this study.
  • Chemotherapy consisted of leucovorin 25 mg/m2/day by 2-hour intravenous infusion, followed by 5-FU 375 mg/m2/day by bolus intravenous infusion, from day I to day 5.
  • The treatment was repeated every 3 to 4 weeks.
  • A total of 51 eligible patients with advanced adenocarcinoma of the pancreas or biliary tract were enrolled.
  • Of 23 enrolled patients with pancreatic adenocarcinoma, one patient showed complete remission with a survival duration of 13 months (response duration was 9 months).
  • Three patients had partial responses (PRs) with survival times of 6, 12, and 15 months, respectively.
  • The median time of overall survival was 6 months (range: 1-15 months).
  • Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7.1%) with survival time of 14 and 16 months, respectively.
  • The median time of overall survival was 6 months (range: 1-16 months).
  • 5-Fluorouracil in modulation with intravenous leucovorin is well tolerated by patients with stage IV pancreatic adenocarcinoma or biliary tract cancer.
  • Although the response rate for patients with pancreatic adenocarcinoma is not better than that achieved using 5-FU monochemotherapy, the 32.1% overall response rate achieved in patients with biliary tract cancer suggests that 5-FU modulation with leucovorin is active in biliary tract cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Fluorouracil / administration & dosage. Leucovorin / administration & dosage. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Confidence Intervals. Drug Interactions. Female. Humans. Male. Middle Aged. Mucous Membrane / drug effects. Neoplasm Staging. Palliative Care. Remission Induction. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955877.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


77. Mambrini A, Sanguinetti F, Pacetti P, Caudana R, Iacono C, Guglielmi A, Guadagni S, Del Freo A, Fiorentini G, Cantore M: Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience. In Vivo; 2006 Nov-Dec;20(6A):751-5
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience.
  • The final results of a new regimen given intra-arterially for unresectable pancreatic cancer (UPC) are presented.
  • No complications related to the angiographic procedure took place, but three tunica intima dissections of the iliac artery occurred; 7.6% of patients with partial responses and 50.7% with stable disease were observed.
  • Two hundred and one patients have died; median overall survival was 9.2 months: 10.5 and 6.6 for stage III and IV, respectively.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Celiac Artery. Chemotherapy, Cancer, Regional Perfusion. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / therapeutic use. Epirubicin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Infusions, Intra-Arterial. Leucovorin / therapeutic use. Male. Middle Aged. Neoplasm Staging. Pain / drug therapy. Pain / physiopathology. Pancreas / pathology. Pancreas / surgery. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203761.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; BG3F62OND5 / Carboplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; FLEC protocol
  •  go-up   go-down


78. Oman M, Lundqvist S, Gustavsson B, Hafström LO, Naredi P: Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer. Cancer Chemother Pharmacol; 2005 Dec;56(6):603-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
  • BACKGROUND: Systemic palliative treatment with chemotherapy against advanced pancreas cancer has low effectiveness despite considerable toxicity.
  • AIM: To investigate the safety, toxicity and tumour response of intraperitoneal 5-Fluorouracil (5-FU) with intravenous Leucovorin and to monitor 5-FU pharmacokinetics in plasma during intraperitoneal instillation with and without vasopressin in patients with non-resectable pancreas cancer.
  • PATIENTS/METHODS: Between 1994 and 2003, 68 patients with non-resectable pancreas cancer TNM stage III and IV, were enrolled to receive intraperitoneal5-FU instillation 750-1500 mg/m2 and intravenous Leucovorin 100 mg/m2 for two days every third week.
  • RESULTS: The treatment was well tolerated with minor toxicity.
  • Time to progression was 4.4 months (0.8-54.1+), and median survival was 8.0 months (0.8-54.1+).
  • There was a significant reduction of 5-FU Cmax in plasma the second day of treatment if vasopressin was used (3.4+/-2.5 and 6.1+/-5.4 mumol/l, respectively, p<0.05).
  • 5-FU AUC in plasma was not significantly affected by vasopressin either day of treatment.
  • CONCLUSION: Intraperitoneal 5-FU is a safe treatment with low toxicity to patients with non-resectable pancreas cancer.
  • Tumour response was 4.4% and median survival time 8.0 months.
  • Addition of vasopressin did not significantly decrease plasma 5-FU AUC but reduced Cmax on day 2 of treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorouracil / administration & dosage. Hemostatics / administration & dosage. Pancreatic Neoplasms / drug therapy. Vasopressins / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. VASOPRESSIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047145.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Clinical Trial, Phase IV; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Hemostatics; 11000-17-2 / Vasopressins; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


79. Malayeri R, Ghassemboland M, Ranjpoor F, Maadi A: Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma. Hematol Oncol Stem Cell Ther; 2008 Oct-Dec;1(4):221-4
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine/5-flourouracil/leucovorin for the treatment of advanced pancreatic carcinoma.
  • BACKGROUND AND OBJECTIVE: The response rate and median survival with gemcitabine monotherapy, although considered the standard treatment for inoperable and metastatic pancreatic cancer, is relatively poor.
  • We tested the efficacy and toxicity of a chemotherapy protocol consisting of gemcitabine, 5-fluorouracil (5-FU) and leucovorin in patients with inoperable or metastatic pancreatic cancer, which was shown to improve median survival in a small phase II trial.
  • PATIENTS AND METHODS: Patients older than 18 years of age with histologically or cytologically confirmed adenocarcinoma of the pancreas and bidimensionally measurable disease, and who were chemotherapy- and radiotherapy-naïve, were treated with a chemotherapy protocol consisting of gemcitabine 1250 mg/m2 on day 1, 5-FU 450 mg/m2 and leucovorin 100 mg/m2 on days 1-3.
  • The treatment was repeated every 2 weeks.
  • RESULTS: In an-intention-to-treat analysis, of 37 patients with pancreatic cancer (27 males, 10 females) (67.6% stage IVb) there were 7 (18.9%) objective partial responses (95% confidence interval, 8.33% to 29), 14 (37.8%) patients had stable disease and 16 (43.2%) had progressive disease.
  • The median response time was 3 months (range, 1.5 to 7.0 months).
  • Median overall survival time was 6.5 months (range, 1.0 to 15.5 months).
  • The response to chemotherapy was not different between males and females (P = .971).
  • No grade III/IV toxicities were seen.
  • CONCLUSION: Despite our poor survival data, the combination of gemcitabine with 5-/FU and leucovorin is an active and well-tolerated regimen in patients with pancreatic cancer that merits further evaluation in prospective randomized studies.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20058477.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


80. Tonai K, Kitasato Y, Kawakami T, Kondo H, Koga T, Takata S, Katafuchi R, Kawasaki M: [Autopsy case of rapidly progressive pulmonary spindle cell carcinoma with multiple metastases to the brain and pancreas]. Nihon Kokyuki Gakkai Zasshi; 2009 Sep;47(9):828-32
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autopsy case of rapidly progressive pulmonary spindle cell carcinoma with multiple metastases to the brain and pancreas].
  • Chest X-ray and computed tomography showed a large mass lesion in the right lower lobe of the lung.
  • We diagnosed primary non-small cell lung cancer; cT3N1M1 stage IV.
  • Systemic chemotherapy using carboplatin and paclitaxcel was performed.
  • However, the treatment had no effect and he died two months after admission.
  • An autopsy showed pulmonary spindle cell carcinoma, with multiple metastases to the brain, pancreas, etc.
  • Pulmonary spindle cell carcinoma had been recognized as a variant of the squamous cell carcinoma for years, however, in the recent WHO and Japanese classification of lung tumors, it was redefined as an independent histological type.
  • It is a rare form of lung cancer, representing 0.2 to 0.3% of all primary pulmonary malignancies and seems to have poor prognosis.
  • We need to pay more attention to this type of lung cancer.
  • [MeSH-major] Autopsy. Brain Neoplasms / secondary. Carcinoma / secondary. Lung Neoplasms / pathology. Pancreatic Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827589.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


81. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, Jarnagin WR, DeMatteo RP, D'Angelica MI, Barakat RR, Chi DS: The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol; 2006 Dec;103(3):1083-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
  • OBJECTIVES: To determine the survival impact of adding extensive upper abdominal surgical cytoreduction to standard surgical techniques for advanced ovarian cancer.
  • METHODS: The records of all patients with stages IIIC-IV epithelial ovarian cancer who underwent primary surgery at our institution from 1998 to 2003 were reviewed.
  • Group 1 patients required extensive upper abdominal surgery, such as diaphragm peritonectomy/resection, resection of parenchymal liver or porta hepatis disease and/or splenectomy with or without distal pancreatectomy, to achieve optimal cytoreduction (residual disease<or=1 cm).
  • Primary outcome measures were response to primary chemotherapy, progression-free survival, and overall survival.
  • Prognostic factors significant on multivariate analysis included stage, optimal status, and ascites.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Databases, Factual. Diaphragm / surgery. Disease-Free Survival. Female. Humans. Liver / surgery. Middle Aged. Neoplasm Staging. New York City. Pancreas / surgery. Peritoneum / surgery. Spleen / surgery. Survival Analysis. Treatment Outcome


82. Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, Tepper JE: Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer; 2006 Aug 7;95(3):260-5
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study.
  • The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined.
  • Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (40 mg m(-2)) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy in 5(1/2) weeks).
  • Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment.
  • Characteristics: median age 61 years (range 35-79); 24 females (58%); 73% stage T3/T4; and 70% lymph node positive.
  • Grade III/IV gastrointestinal or haematologic toxicities were infrequent.
  • The median survival was 18.3 months, while the median time to disease recurrence was 10.3 months.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):55-60 [10550827.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3218-23 [8205542.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):785-91 [10837965.001]
  • [Cites] J Clin Oncol. 2000 Oct 1;18(19):3384-9 [11013279.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):792-9 [11157033.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1317-22 [11483344.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2246-53 [11489798.001]
  • [Cites] Int J Pancreatol. 2001;29(1):9-18 [11560155.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3263-8 [11595723.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):974-81 [11704320.001]
  • [Cites] J Clin Oncol. 2001 Nov 15;19(22):4202-8 [11709563.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1305-10 [12654442.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):974-80 [12829132.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1461-7 [15275733.001]
  • [Cites] Int J Gastrointest Cancer. 2003;34(2-3):107-16 [15361643.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):444-52 [15380578.001]
  • [Cites] Invest New Drugs. 1994;12(1):29-34 [7960602.001]
  • [Cites] Semin Oncol. 1995 Aug;22(4 Suppl 11):68-71 [7481848.001]
  • [Cites] Br J Cancer. 1996 Jan;73(1):101-5 [8554969.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):867-72 [8598364.001]
  • [Cites] Semin Oncol. 1996 Oct;23(5 Suppl 10):65-71 [8893885.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Radiat Oncol Investig. 1997;5(2):62-71 [9303059.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):777-82 [9815749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1125-35 [10421547.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2208-12 [10561277.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3675-80 [2340517.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;27(4):258-62 [1998982.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):52-6 [8318420.001]
  • [CommentIn] Nat Clin Pract Oncol. 2007 Mar;4(3):148-9 [17245345.001]
  • (PMID = 16868545.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA081851; United States / NCI NIH HHS / CA / 1 U10 CA81851
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Other-IDs] NLM/ PMC2360633
  •  go-up   go-down


83. Saif MW, Dai T: Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma. JOP; 2010;11(3):277-9
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitomycin-induced interstitial pneumonitis in a patient with BRCA2 associated metastatic pancreatic carcinoma.
  • [MeSH-minor] Aged. Humans. Male. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / secondary. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Interstitial Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442529.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down






Advertisement